Document:

<PAGE>
                                                                   EXHIBIT 10.30

                          TECHNOLOGY TRANSFER AGREEMENT

     THIS TECHNOLOGY TRANSFER AGREEMENT (the "Agreement") is entered into
effective as of the 20th day of December 2006 (the "Effective Date"), by and
between Mallinckrodt Inc., a Delaware corporation, with a place of business at
675 McDonnell Boulevard, Hazelwood, Missouri 63042 ("MALLINCKRODT"), and
Molecular Insight Pharmaceuticals, Inc., a Delaware corporation, with an office
at 160 Second Street, Cambridge, Massachusetts 02142 ("MIP").

     WITNESSETH THAT:

     WHEREAS, MIP plans to enter a license agreement with Novartis Pharma AG
("Novartis") for the right to make, use, sell, offer for sale and import the
Product (as defined in Section 1 below); and

     WHEREAS, MALLINCKRODT owns or is the licensee of certain Patent Rights (as
defined in Section 1 below), claiming a method of stabilization of
radiopharmaceuticals; and

     WHEREAS, MALLINCKRODT has technology and capability to manufacture Vials
(as defined in Section 1 below) and the Product; and

     WHEREAS, MIP desires to obtain a license to the Patent Rights and
Technology (as defined in Section 1 below), and to receive a transfer of the
Technology for the Vials and the Product as detailed in EXHIBIT B; and

     WHEREAS, MALLINCKRODT is willing to grant the license and to provide the
transfer of the Technology upon the terms and conditions set forth in this
Agreement;

     NOW THEREFORE, in consideration of the premises and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, MALLINCKRODT and MIP agree as follows:

1. DEFINITIONS. Wherever used in this Agreement, the following capitalized terms
shall have the meanings set forth below:

     1.1 "AFFILIATE" means any entity that directly or indirectly controls or is
controlled by or is under common control with a Party to this Agreement. For
purposes of this definition, "control" or "controlled" means ownership directly
or through one or more Affiliates, of fifty percent (50%) or more of the shares
of stock entitled to vote for the election of directors, in the case of a
corporation, or fifty percent (50%) or more of the equity interest in the case
of any

<PAGE>

other type of legal entity, status as a general partner in any partnership, or
any other arrangement whereby a Party controls or has the right to control the
board of directors or equivalent governing body of a corporation or other
entity, or the ability to cause the direction of the management or policies of a
corporation or other entity.

     1.2 "AGREEMENT" shall mean this Technology Transfer Agreement together with
all exhibits, schedules and appendices hereto, all as the same may be amended,
modified or supplemented from time-to-time in accordance with the terms of this
Agreement.

     1.3 "CHANGE OF CONTROL" shall mean any of the following events: (i) any
Third Party (or group of Third Parties acting in concert) becomes the beneficial
owner, directly or indirectly, of fifty percent (50%) or more of the voting
power of the stock then outstanding of MIP; (ii) MIP consolidates with or merges
into another corporation or entity, or any corporation or entity consolidates
with or merges into MIP, in either event pursuant to a transaction in which
fifty percent (50%) or more of the total voting power of the stock outstanding
of the surviving entity normally entitled to vote is not held by Persons holding
more than fifty percent (50%) of the outstanding shares of MIP prior to such
consolidation or merger; (iii) any Third Party (or group of Third Parties acting
in concert) obtains the power to direct or cause the direction of the management
and policies of MIP by any lawful means whatsoever; or (iv) MIP conveys,
transfers or leases all or substantially all of its assets.

     1.4 "COMPOUND" means DOTA-Tyr(3)-Octreotide.

     1.5 "EFFECTIVE DATE" shall mean the later to occur of (i) the date upon
which MALLINCKRODT receives written notice from MIP that MIP has executed the
agreement with Novartis as referenced in Section 8 hereof and (ii) the date upon
which the Termination Letter shall have been executed by and between
MALLINCKRODT and Novartis.

     1.6 "FDA" means the United States Food and Drug Administration and any
successor agency thereto.

     1.7 "GOOD MANUFACTURING PRACTICES" or "GMP" means the then current Good
Manufacturing Practices as such term is defined from time to time by the FDA or
other relevant governmental authority having jurisdiction over the development,
manufacture or sale of the Product in any other country pursuant to its
regulations, guidelines or otherwise.

     1.8 "MALLINCKRODT CONFIDENTIAL INFORMATION" means all Technology, data and
other information that is disclosed by MALLINCKRODT to MIP during the course of
providing the technology transfer services under this Agreement to the extent
that such

                                        2

<PAGE>

information as of the date of disclosure to MIP is not (i) known to MIP other
than by virtue of a prior confidential disclosure to MIP by MALLINCKRODT; or
(ii) disclosed in published literature, or otherwise generally known to the
public through no fault or omission of MIP; or (iii) obtained from a Third Party
free from any obligation of confidentiality to MALLINCKRODT.

     1.9 "MIP CONFIDENTIAL INFORMATION" means all information about MIP's
technical requirements with respect to the Product which is disclosed by MIP to
MALLINCKRODT and designated "Confidential" in writing by MIP at the time of
disclosure to MALLINCKRODT to the extent that such information is not (i) as of
the date of disclosure to MALLINCKRODT demonstrably known to MALLINCKRODT other
than by virtue of a prior confidential disclosure to MALLINCKRODT by MIP; or
(ii) as of the date of disclosure or thereafter is disclosed in published
literature, or otherwise generally known to the public through no fault or
omission of MALLINCKRODT; or (iii) obtained from a Third Party free from any
obligation of confidentiality to MIP; or (iv) MALLINCKRODT can demonstrate by
competent evidence was developed by MALLINCKRODT or its Affiliates without
access to or the benefit of MIP Confidential Information. MIP will not disclose
any information to MALLINCKRODT regarding MIP's marketing plans or
commercialization with respect to the Product or to the Indium 111 labelled
Compound for dosimetry planning for OctreoTher therapy delivery and to the
extent disclosed, such information shall not be deemed MIP Confidential
Information for purposes of this Agreement and MALLINCKRODT shall not be under
any limitations with respect thereto.

     1.10 "MIP FIELD" means human oncology therapeutic use.

     1.11 "OCTREOTHER(R)" means the trademark selected and owned by Novartis for
the Product.

     1.12 "PARTY" OR "PARTIES" shall mean MIP or MALLINCKRODT, or MIP and
MALLINCKRODT, whichever the context admits.

     1.13 "PATENT RIGHTS" means the patents and patent applications listed in
EXHIBIT A, and patents issuing on them, including any division, continuation,
continuation-in-part, renewal, extension, re-examination, reissue or foreign
counterpart thereof.

     1.14 "PERSON" shall mean any individual, corporation, partnership,
association, joint stock company, trust, unincorporated organization or
government or political subdivision thereof.

                                       3

<PAGE>

     1.15 "PRODUCT" means the OctreoTher Hot Liquid which is the radiolabeled
peptide (90)Y DOTA-Tyr(3)-Octreotide (Yttrium ((90)Y) SMT 487) in a solution
prepared from the reconstituted Vials.

     1.16 "REGULATORY AUTHORITY" shall mean the FDA or any foreign counterpart
or additional governmental or regulatory agencies in the Territory with
responsibility for marketing approval or authorization of the Product.

     1.17 "TECHNOLOGY" means and is limited to the specific materials, technical
information, know-how, expertise, trade secrets and the associated documentation
in MALLINCKRODT's possession and required for:

          -    the manufacturing and quality control of the Vials; and

          -    the manufacturing and quality control of the Product.

MIP acknowledges that the term "Technology" does not include any know-how,
expertise or trade secret information, if any, that MALLINCKRODT may have
regarding the labelling of the Compound with Indium-111. Without limiting the
generality of the preceding sentence, MALLINCKRODT shall be under no obligation
whatsoever to provide a Technology transfer to MIP with respect to the labelling
of the Compound with Indium-111.

     1.18 "TERRITORY" shall mean all of the countries and territories of the
world.

     1.19 "TERMINATION LETTER" shall mean an agreement to be entered into by
MALLINCKRODT and Novartis providing for the termination of (i) that certain
agreement, dated December 1, 1992, between Sandoz Pharma Ltd. (now Novartis) and
Mallinckrodt Medical Inc. (now MALLINCKRODT) relating to the development,
manufacture and marketing of molecules for radiodiagnostic and radiotherapeutic
purposes and (ii) that certain agreement, dated October 1996, under which
MALLINCKRODT and Novartis agreed to collaborate in the development, manufacture
and marketing of the Product.

     1.20 "THIRD PARTY" shall mean any Person or other entity other than MIP,
MALLINCKRODT or their respective Affiliates.

     1.21 "VIAL" means the OctreoTher SMT 487 Reaction Vial which is a vial
containing lyophilized material comprised of DOTA-Tyr(3)- Octreotide, gentisic
acid, inositol, ascorbic acid, and sodium hydroxide that is reconstituted to
make the Product.

2. GRANT OF LICENSE, TERM, RIGHTS AND OBLIGATIONS.

     2.1 LICENSE GRANTED TO MIP UNDER THE PATENT RIGHTS AND TECHNOLOGY. Subject
to

                                       4

<PAGE>

the terms, conditions and limitations of this Agreement, MALLINCKRODT hereby
grants to MIP a non-exclusive, worldwide license under all of MALLINCKRODT's
right, title and interest in the Patent Rights and Technology, to manufacture,
use, sell, offer for sale and import the Product in the MIP Field, as well as to
use the Indium 111 labelled Compound for dosimetry purposes in relation to the
Product therapy administration; provided that MIP can only exercise the
foregoing rights with respect to an Indium 111 labelled Compound to the extent
the FDA or other Regulatory Authority expressly requires the development and use
thereof for dosimetry purposes as a condition to its approval of the Product for
marketing and sale, and provided further that MIP may under no circumstances
market and sell an Indium-111 labelled Compound separately as a diagnostic
imaging agent (i.e., the Indium-labelled Compound can only be marketed and sold
for dosimetry purposes in relation to Product therapy administration). Except as
specifically provided in this Agreement, no licenses are granted by MALLINCKRODT
and MALLINCKRODT retains all other rights under the Patent Rights and the
Technology.

     MIP shall have the right to grant sublicenses with respect to the license
rights provided for in this Section 2.1 solely on the following terms and
conditions.

          (a) Without MALLINCKRODT'S prior written consent, which MALLINCKRODT
may grant or withhold in its sole and absolute discretion, and notwithstanding
anything to the contrary forth in this Agreement, MIP cannot sublicense any
rights to a direct competitor of MALLINCKRODT, as listed in EXHIBIT G.

          (b) In the event MIP intends to grant rights of any nature whatsoever
with respect to the commercialization, including but not limited to the
marketing, promoting, distributing, importing or selling, of the Product to any
Third Party(ies), MIP must first offer any such commercialization rights, in
writing, to MALLINCKRODT. Upon receipt of such offer, MALLINCKRODT shall have
sixty (60) days to inform MIP whether it desires to enter into good faith
negotiations with MIP for a definitive agreement with respect to such rights.
Mallinckrodt's rights under this subsection are subject to MIP's obligation to
first provide Novartis with "rights of first discussions", as set forth in
Section 6.5 of the agreement to be entered into between MIP and Novartis
relating to the Product, as referenced in Section 8 of this Agreement.

          (c) MIP shall in all events remain directly responsible to
MALLINCKRODT for the performance by any sublicensee of any and all obligations
and/or responsibilities assumed by such sublicensee under this Agreement.

                                       5

<PAGE>

          (d) The terms and conditions of any Third Party sublicense shall be
consistent in all respects with the terms of this Agreement.

          (e) MIP shall cause each sublicensee to execute any and all additional
documents reasonably requested by MALLINCKRODT to reflect the conditions set
forth above.

     2.2 TERM OF LICENSE. The term of the license set forth in Section 2.1 shall
commence on the Effective Date and, unless sooner terminated pursuant to Article
9 of this Agreement, shall terminate on a country-by-country basis on the date
when MIP discontinues manufacture and/or sale of the Product, as the case may
be, in such country.

     2.3 TRANSFER OF THE TECHNOLOGY.

          (a) During the period commencing no later than thirty (30) days after
the Effective Date and terminating not later than one-hundred eighty (180) days
thereafter, MALLINCKRODT shall make available research and development and
production personnel to physically transfer the Technology to MIP personnel.
Such MALLINCKRODT personnel shall be knowledgeable about the Technology, shall
be reasonably capable of transferring the Technology to MIP, and shall use
commercially reasonable efforts to transfer the Technology to MIP personnel. MIP
must at all times during the one-hundred eighty (180) period referenced in the
preceding sentence provide knowledgeable and capable personnel to be the
recipients of the transfer of the Technology. Exhibit B is an all-inclusive list
of the specific services to be provided by MALLINCKRODT personnel hereunder.
MALLINCKRODT shall transfer the Technology to MIP on an "AS IS" basis.

          (b) MALLINCKRODT's obligation to provide transfer of the Technology is
in all events limited to ninety (90) work days (i.e., one MALLINCKRODT employee
working ninety (90) days at eight (8) hours per day) or completion by
MALLINCKRODT of the specific services identified in Exhibit B, whichever comes
first.

          (c) For purposes of calculating the amount of time devoted by
MALLINCKRODT personnel to the transfer of Technology required under this
Agreement, each response by MALLINCKRODT to a request by MIP or its Affiliates
for assistance, whether in the form of a written communication, oral request, or
otherwise, shall be accounted for as an expenditure of time equal to the greater
of (i) four (4) hours or (ii) the actual time spent by MALLINCKRODT responding
to the request for assistance. For example, if an employee of MIP requests, by
telephone call, assistance with Technology transfer and a MALLINCKRODT employee
devotes two (2) hours responding to the request, MALLINCKRODT shall, for

                                       6

<PAGE>

purposes of this Agreement, be considered to have provided four (4) hours of
Technology transfer services.

          (d) In the event the MALLINCKRODT personnel referenced above are
required to travel away from their regular place of employment, MIP will
reimburse MALLINCKRODT for all reasonable travel and living expenses incurred by
such personnel upon submission by MALLINCKRODT of an itemized account of
expenses for which it seeks reimbursement. Travel time will be considered
working time of MALLINCKRODT employees for purposes of determining
MALLINCKRODT's compliance with its obligations under this Section.

     2.4 ADDITIONAL TRANSFER OF THE TECHNOLOGY. If, during the first twelve (12)
months this Agreement is in effect, MIP determines that it requires additional
Technology transfer from MALLINCKRODT, MIP shall provide to MALLINCKRODT a list
of its specific additional requirements for MALLINCKRODT's consideration. If the
request is acceptable to MALLINCKRODT in its reasonable discretion, MALLINCKRODT
shall provide up to an additional ninety (90) work days in thirty (30) work day
increments of Technology transfer during a similar period and in the manner set
forth in Section 2.3. MIP shall make the payment described in Section 3(d) prior
to the commencement of such additional Technology transfer.

     2.5 CERTIFICATION BY MALLINCKRODT. Upon completion by MALLINCKRODT of its
obligation(s) to transfer the Technology under Sections 2.3 and/or 2.4 of this
Agreement, MALLINCKRODT shall provide a written certification of completion to
MIP in the form attached to this Agreement as EXHIBIT C. Absent manifest error
demonstrated by MIP, and subject to MIP's rights to additional technical
support, if applicable, as set forth in Section 2.4, such certification shall
for all purposes be deemed conclusive and final evidence of MALLINCKRODT's full
and complete performance of its Technology transfer obligations to MIP.

     2.6 LIAISON. Each of MIP and MALLINCKRODT shall within ten (10) days of the
execution of this Agreement identify a primary contact person to act as liaison
for the purposes of implementing this Agreement.

3. PAYMENTS. MIP shall make the following payments to MALLINCKRODT by wire
transfer in United States Dollars to an account designated by MALLINCKRODT:

          (a) $250,000.00 concurrent with the execution of this Agreement;

                                       7

<PAGE>

          (b) $** upon commencement by MALLINCKRODT of the Technology
     transfer as detailed in Exhibit B;

          (c) $** upon completion of the Technology transfer as detailed
     in Exhibit B; and

          (d) $** for each thirty (30) day increment of the additional
     Technology Transfer pursuant to Section 2.4, payable upon commencement by
     MALLINCKRODT of each such increment.

4. SALE OF OCTREOTHER VIALS.

     4.1 MALLINCKRODT hereby sells and MIP buys the 1,800 Vials in
MALLINCKRODT's possession. The purchase price is U.S. $400,000.00, fifty percent
(50%) of which is payable by wire transfer concurrent with the execution of this
Agreement and the balance of which is payable upon confirmation of delivery to
MIP.

     4.2 Terms of delivery for the Vials shall be FOB, MALLINCKRODT's facility
in Petten, The Netherlands. MALLINCKRODT shall cause the Vials to be shipped
within thirty (30) days after the later of execution of this Agreement and
receipt by MALLINCKRODT of the fifty percent (50%) installment, as described in
Section 4.1 above, unless directed otherwise by MIP and agreed upon by
MALLINCKRODT in its discretion.

     4.3 MALLINCKRODT warrants that the Vials have been manufactured in
accordance with GMP standards and meet the specifications in Section 5.2.1 of
the Yttrium ((90)Y) SMT 487 IND Information Manufacturing Description attached
to this Agreement as EXHIBIT D. MALLINCKRODT MAKES NO OTHER WARRANTY, EXPRESS OR
IMPLIED, WITH RESPECT TO THE VIALS, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE, EXCEPT AS SET FORTH IN SECTION 6.

5. MIP RESPONSIBILITIES. Upon the Effective Date, MIP will be solely
responsible, at its own cost, for all regulatory filings, development and
clinical and commercial manufacture of all Product. MALLINCKRODT will have no
responsibilities or obligation of any kind with respect to these activities.

6. REPRESENTATION AND WARRANTY.

     6.1 MALLINCKRODT represents and warrants to MIP that, upon execution of the

                       *Confidential Treatment Requested*

                                       8

<PAGE>

Termination Agreement by Novartis, it will have the right to grant the license
granted pursuant to Section 2.1 of this Agreement, and that the license so
granted will not conflict with or violate the terms of any agreement between
MALLINCKRODT and any Third Party.

7. TREATMENT OF CONFIDENTIAL INFORMATION.

     7.1 CONFIDENTIALITY.

          7.1.1 Subject to MIP's rights with respect to the licenses as
specifically provided for in Section 2.1 of this Agreement, MIP and MALLINCKRODT
each agree that during the term of this Agreement and for five (5) years
thereafter, it will keep confidential, and will cause its Affiliates and
sublicensees to keep confidential, all MALLINCKRODT Confidential Information or
MIP Confidential Information, as the case may be, which is disclosed to it or to
any of its Affiliates and sublicensees pursuant to this Agreement. Neither MIP,
its Affiliates or sublicensees, nor MALLINCKRODT shall use Confidential
Information of the other Party except as expressly permitted under this
Agreement.

          7.1.2 Each Party agrees that it will disclose the other Party's
Confidential Information to its officers, employees, agents or Affiliates only
if and to the extent necessary to carry out its responsibilities under this
Agreement and shall limit disclosures to the extent possible consistent with
such responsibilities. MALLINCKRODT agrees not to disclose MIP Confidential
Information to any Third Parties under any circumstance without written
permission from MIP. MALLINCKRODT shall take such action, and shall cause its
Affiliates to take such action, to preserve the confidentiality of MIP
Confidential Information as it would customarily take to preserve the
confidentiality of its own Confidential Information. Upon termination of this
Agreement, MALLINCKRODT will, upon MIP's written request, either return or, in
MALLINCKRODT's discretion, destroy all the MIP Confidential Information
disclosed to it by MIP pursuant to this Agreement, including all copies and
extracts of documents, within sixty (60) days of the request except for one (1)
copy which may be kept for the purpose of complying with continuing obligations
under this Agreement.

          7.1.3 The Parties represent that all employees who shall have access
to Confidential Information are or will be bound by agreements to maintain such
information in confidence.

          7.1.4 Notwithstanding any of the foregoing provisions, MIP
specifically acknowledges and agrees that all confidential and proprietary
information provided by

                                       9

<PAGE>

MALLINCKRODT to MIP in connection with the negotiation, execution and
performance of this Agreement shall also be and remain subject to the terms of
that certain Confidentiality Agreement, dated November 14, 2005, between the
Parties (the "MALLINCKRODT Confidentiality Agreement.") In the event of any
inconsistencies between the terms of this Agreement and the MALLINCKRODT
Confidentiality Agreement, the terms of the MALLINCKRODT Confidentiality
Agreement shall govern, except that MIP shall, without regard to the terms of
the MALLINCKRODT Confidentiality Agreement, be authorized to communicate
MALLINCKRODT Confidential Information to a permitted sublicensee hereunder (as
provided for in Section 2.1) to the extent required for the performance by such
permitted sublicensee of the obligations that are subject to the sublicense.

     7.2 PUBLICITY. Except as required by law, and except for a mutually
approved press release to be issued upon the signing of this Agreement, neither
Party may disclose the terms of this Agreement without the written consent of
the other Party; provided, however, that MIP may disclose the terms, or provide
copies, of this Agreement as necessary in the normal course of business to
bankers, investors and others in order to obtain financing.

     7.3 DISCLOSURE REQUIRED BY LAW. If MALLINCKRODT is requested to disclose
MIP Confidential Information in connection with a legal or administrative
proceeding or is otherwise required by law to disclose the Confidential
Information, it will give MIP prompt notice of such request. MIP may seek an
appropriate protective order or other remedy or waive compliance with the
provisions of this Agreement. If MIP seeks a protective order or other remedy,
MALLINCKRODT will cooperate at MIP's sole cost and expense. If MIP fails to
obtain a protective order or waive compliance with the relevant provisions of
this Agreement, MALLINCKRODT will disclose only that portion of MIP Confidential
Information which its legal counsel determines it is required to disclose.

8. NO OTHER AGREEMENTS. Except for the MALLINCKRODT Confidentiality Agreement,
this Agreement is the sole agreement between the Parties with respect to the
subject matter hereof and supersedes all other agreements and understandings
between the Parties with respect to same; provided, however, the execution of
the proposed agreement between MIP and Novartis with respect to the Product
prior to or on even date with this Agreement, together with the execution by
MALLINCKRODT and Novartis of the Termination Agreement, are condition precedents
to the force and effectiveness of this Agreement. If such agreement is not
executed in

                                       10

<PAGE>

the time described, this Agreement will lapse and the Parties will have no
obligation of any kind to each other; provided that such lapse will have no
effect on the continuing enforceability of the MALLINCKRODT Confidentiality
Agreement in accordance with its terms.

9. TERMINATION AND DISENGAGEMENT.

     9.1 MATERIAL BREACH. If either MIP or MALLINCKRODT shall breach any
material obligation contained in this Agreement and, in the case of a breach
capable of remedy, such breach shall not be cured within sixty (60) days (ten
(10) days with respect to a payment default) after written notice to the
breaching Party, the Party not in breach may terminate this Agreement by notice
without prejudice to the accrued rights of either Party.

     9.2 TERMINATION FOR INSOLVENCY. Either Party may terminate this Agreement
immediately upon delivery of written notice to the other Party: (i) upon the
institution by or against the other Party of insolvency, receivership or
bankruptcy proceedings or any other proceedings for the settlement of the other
Party's debts; provided, however, with respect to involuntary proceedings, that
such proceedings are not dismissed within one hundred and twenty (120) days;
(ii) upon the other Party's making an assignment for the benefit of creditors;
or (iii) upon the other Party's dissolution or ceasing to do business.

     9.3 CHANGE OF CONTROL. MALLINCKRODT may terminate this Agreement
immediately in the event there is a Change in Control, provided such Change in
Control results in MIP being owned by a direct competitor of MALLINCKRODT, as
listed on Exhibit G hereto.

     9.4 EFFECT OF TERMINATION.

          (a) The expiration of termination of this Agreement for any reason
shall not relieve the Parties from any obligations that accrued prior to such
expiration or termination, including without limitation MALLINCKRODT's right to
receive all payments accrued hereunder as of the effective date of expiration or
termination. In addition, except where explicitly elsewhere provided herein,
termination of this Agreement for any reason, or expiration of this Agreement,
will not affect any rights or obligations which, from the context thereof, are
intended to survive termination or expiration of this Agreement.

          (b) In the event this Agreement is rightfully terminated by
MALLINCKRODT pursuant to Sections 9.1, 9.2 or 9.3, (i) all of MIP's rights to
the Patent Rights and the Technology shall immediately revert to MALLINCKRODT,
including but not limited to all rights under the license conveyed pursuant to
Section 2.1 of this Agreement, and

                                       11

<PAGE>

(ii) MALLINCKRODT shall be entitled to immediately cease all Technology transfer
activities otherwise remaining to be performed under this Agreement.

          (c) In the event this Agreement is rightfully terminated by MIP
pursuant to Sections 9.1 or 9.2, MIP's license rights in and to the Patent
Rights and the Technology shall nevertheless continue in full force and effect
in accordance with the terms of this Agreement.

10. INDEMNIFICATION. MIP hereby agrees to indemnify, defend and hold harmless
MALLINCKRODT (and all officers, directors, employees, agents and other
Affiliates of MALLINCKRODT) for any and all claims, liabilities, damages,
losses, costs or expenses (including but not limited to reasonable attorneys'
fees) arising from or in connection with (i) any breach by MIP of a material
obligation under this Agreement, (ii) clinical trials pursued by MIP, its
Affiliates or sublicensees with respect to the Product or the Compound or (iii)
the development, manufacture, marketing and/or sale of the Product by MIP, its
Affiliates or sublicensees. MIP shall choose legal counsel, shall control the
defense of such claim or action and shall have the right to settle same on such
terms and conditions it deems advisable.

11. LIMITATION OF DAMAGES. Neither Party nor their respective Affiliates shall
have any liability for any special, incidental or consequential damages,
including but not limited to loss of opportunity, revenue or profit, in
connection with or arising out of this Agreement, even if it shall have been
advised of the possibility of such damages.

12. NOTICES. All notices shall be in writing mailed via certified mail, return
receipt requested, courier, or facsimile or other e-mail transmission addressed
as follows, or to such other address as may be designated from time to time:

     IF TO MIP: Molecular Insight Pharmaceuticals, Inc.
                160 Second Street
                Cambridge, Massachusetts 02142
                Attn: Vice President, Commercial and Business Development

     WITH COPY TO: Joshua A. Kalkstein, Esq.
                   Robinson & Cole LLP

                                       12

<PAGE>

                   One Boston Place
                   Boston, MA 02108

     IF TO MALLINCKRODT: Mallinckrodt Inc.
                         675 McDonnell Blvd.
                         St. Louis, MO 63134
                         Attn: President, Imaging Division

     WITH COPY TO: Mallinckrodt Inc.
                   675 McDonnell Blvd.
                   St. Louis, MO 63134
                   Attn: Vice President Legal, Imaging Division

Notices shall be deemed given as of the date received.

13. GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware without giving effect to the
principles of conflicts of laws thereof or any other law that would apply the
law of another jurisdiction.

14. MISCELLANEOUS.

     14.1 BINDING EFFECT. This Agreement shall be binding upon and inure to the
benefit of the Parties and their respective legal representatives, heirs,
successors and permitted assigns.

     14.2 HEADINGS. Paragraph headings are inserted for convenience of reference
only and do not form a part of this Agreement.

     14.3 COUNTERPARTS. This Agreement may be executed simultaneously in two or
more counterparts, each of which shall be deemed an original. Signatures may be
transmitted via facsimile, thereby constituting the valid signature and delivery
of this Agreement.

     14.4 AMENDMENT; WAIVER; ETC. This Agreement may be amended, modified,
superseded or cancelled, and any of the terms may be waived, only by a written
instrument executed by each Party or, in the case of waiver, by the Party or
Parties waiving compliance. The delay or failure of any Party at any time or
times to require performance of any provisions shall in no manner affect the
rights at a later time to enforce the same. No waiver by any Party

                                       13

<PAGE>

of any condition or of the breach of any term contained in this Agreement,
whether by conduct, or otherwise, in any one or more instances, shall be deemed
to be, or considered as, a further or continuing waiver of any such condition or
of the breach of such term or any other term of this Agreement.

     14.5 NO THIRD PARTY BENEFICIARIES. No Third Party including any employee of
any Party to this Agreement, shall have or acquire any rights by reason of this
Agreement. Nothing contained in this Agreement shall be deemed to constitute the
Parties as partners with each other or any Third Party.

     14.6 ASSIGNMENT AND SUCCESSORS. MALLINCKRODT may not assign its Technology
transfer obligations under this Agreement to any Third Party without MIP's
consent, which will not be unreasonably withheld, other than to an Affiliate,
any purchaser of all or substantially all of MALLINCKRODT's assets, or to any
successor corporation resulting from any merger or consolidation of MALLINCKRODT
with or into such corporation. MIP may not transfer or assign any of its rights
or obligations under this Agreement without the express, prior written consent
of MALLINCKRODT, which MALLINCKRODT may withhold in its sole discretion in the
event the proposed assignee is a MALLINCKRODT competitor as listed on Exhibit G
hereto. With respect to any other assignee (i.e., an assignee not listed on
Exhibit G), MALLINCKRODT will not unreasonably withhold its consent to the
proposed transfer or assignment. Any attempted assignment or transfer in
contravention of this Section shall, at the option of the non-assigning Party,
be null and void and of no effect. No assignment shall release either Party from
responsibility for the performance of any accrued obligation of such Party
hereunder.

     14.7 FORCE MAJEURE. Neither MIP nor MALLINCKRODT shall be liable for
failure of or delay in performing obligations (other than payment obligations)
set forth in this Agreement, and neither shall be deemed in breach of its
obligations, if such failure or delay is due to natural disasters or any causes
reasonably beyond the control of MIP or MALLINCKRODT.

     14.8 SEVERABILITY. If any provision of this Agreement is or becomes invalid
or is ruled invalid by any court of competent jurisdiction or is deemed
unenforceable, it is the intention of the Parties that the remainder of the
Agreement shall not be affected so long as the essential benefits of this
Agreement remains enforceable and obtainable.

                                       14

<PAGE>

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed
by their duly authorized representatives as of the date first above written.

MOLECULAR INSIGHT                       MALLINCKRODT INC.
PHARMACEUTICALS, INC.

By: /s/ David Barlow                    By: /s/ Steve Hanley
    ---------------------------------       ------------------------------------
    David Barlow                            Steve Hanley

Title:  -----------------------------   Title: ---------------------------------
Chairman and CEO, Molecular             President, Imaging Division
Insight Pharmaceuticals, Inc.

Date: December 19, 2006                 Date: 12/20/06
      -------------------------------        -----------------------------------

                                       15

<PAGE>

                                    EXHIBIT A

                                  US 5,384,113

                                  EP 600 992B1

                                        AT 196428T
                                        BE 600 992
                                        CH 600 992
                                        DE 692231469T
                                        DK 600 992
                                        ES 2150916T
                                        FR 600 992
                                        GB 600 992
                                        GR 3035067T
                                        IT 600 992
                                        LU 600 992
                                        NL 600 992
                                        SE 600 992

                                   CA 2113995C

                                   JP 6510539T

                                       16
<PAGE>

                                    EXHIBIT B

     Below are the services to be provided by MALLINCKRODT for the transfer of
the Technology for the Vials and the Product to MIP. The objective of this
technology transfer is for MALLINCKRODT to provide MIP with sufficient
information and training to enable MIP to manufacture and quality control the
Vials and the Product. A timeline of activities described below appears in
EXHIBIT E.

B.1. Documentation for Vials (OctreoTher Reaction Vial) and Product (OctreoTher
Hot Liquid)

The following documents will be provided by MALLINCKRODT to MIP at least 10
business days prior to the commencement of the Transfer of Technology as
described in Section 2.3, unless otherwise agreed upon by MALLINCKRODT and MIP:

     -    R&D Reports as per Table 1, in English and in both hard copy and
          electronic pdf document format.

     -    Standard Operating Procedures as per Table 2, in the original Dutch
          and in English and in both hard copy and electronic Word document
          format.

     -    Regulatory Information Documents as per Table 3, in English and in
          both hard copy and electronic Word document format.

     -    Documents pertaining to the lyophilization process or the equipment
          necessary for the manufacturing and quality control of the Vials and
          the Product as per Table 4, in English or in Dutch and in either hard
          copy or electronic format.

     -    In addition to the items listed in Tables 1, 2, 3 and 4, MALLINCKRODT
          will provide to MIP any additional documents identified during the
          Transfer of Technology that already exist and are readily available to
          MALLINCKRODT, are required for the manufacturing and quality control
          of the Vials and the Product, and are requested by MIP.

                                       17

<PAGE>

                              TABLE 1. R&D REPORTS

<TABLE>
<CAPTION>
Number                                    Title                                       Report No.
------                                    -----                                       ----------
<S>      <C>                                                                       <C>
   1     Suitability test for a new crimp capsule for OctreoTher bottles
         (Helvoet code 1C325-3-C39)                                                    01ewe03r

   2     IN-PROCESS-CONTROL OF 90Y INCORPORATION DURING OCTREOTHERTM PRODUCTION.       01WGO01R
         APPROPRIATE OR INAPPROPRIATE

   3     OCTREOTHER CONSISTENCY RUNS STABILITY STUDY                                   05WGO00R

   4     MEASUREMENT OF YTTRIUM (90Y) BREMMSSTRAHLUNG                                  03MJ098R

   5     Water content in OctreoTher reaction mixture.                             03mpa02R (version
         Validation of the method.                                                     2) + memo

   6     Stability of NaCl 0.9% purged with Nitrogen for OctreoTher production         04mpa01r

   7     Quality testing of Reaction Mixture for OctreoTher PO: 70190                  05mjo03R

   8     Stability of NaCl 0.9% purged with Nitrogen for OctreoTher production.
         FM 257 stopper vs. FM 259 Stopper                                             05mpa02r

   9     OctreoTher consistency runs. Stability Study.                                 05wgo00r

  10     Scale up production process OctreoTher Novartis B220x clinical studies        06evw02r

  11     STABILITY STUDY OCTREOTHERTM REACTION MIXTURES INTERIM REPORT                 06WGO00R

  12     Annual Overview OctreoTherTM Productions 2003                                 07mjo04r

  13     Bone marrow dosimetry consequences by widening the specification for
         free 90Y in therapy with OctreoTher                                           07MKO00R

  14     JUSTIFICATION FOR THE OF ACID INTRODUCTION OF ASCORBIC ACID IN THE
         FORMULATION OF OCTREOTHER BULKSOLUTION                                        08MJO02R

  15     PRODUCTION AND QUALITY CONTROL OF SMT487                                      08MJO97R
         FORMULATION FOR USE IN THE SUB-ACUTE TOXICITY STUDY

  16     PRODUCTION AND QUALITY CONTROL OF SMT487 FORMULATION FOR USE IN THE
         ACUTE TOXICITY STUDY                                                          09MJ097R

  17     Feasibility of heat sterilization of Octreother (Y90)                         09MJ098R

  18     OCTREOTHER CONSISTENCY RUNS and STABILITY STUDY OF VIALS CONTAINING
         3330 RESPECTIVELY 4440 MBq Y-90 OCTREOTHER                                    09WGO01R

  19     Overview OctreoTher(TM) productions 2002                                      10ewe03r

  20     Stability Study OctreoTher Reaction Mixtures                                  11mjo02r

  21     Annual Overview OctreoTher(TM) Productions 2004                               10mjo05r

  22     Non-radioactive Testing of OctreoTher Production Process in the
         Hot Liquid Facility                                                           12mjo99r

  23     OCTREOTHER CONSISTENCY RUNS OF ADAPTED PRODUCTION PROCESS.
         STABILITY STUDY                                                               14WGO00R

  24     Identification of an impurity visible in HPLC analysis of Yttrium
         labelled DOTA-Tyr3-octreotide                                                 16MJ098R

  25     DETERMINATION OF EXCIPIENTS IN REACTION VIALS FOR OCTREOTHER
         VALIDATION OF THE METHOD                                                      17MJO97R
</TABLE>

                                       18

<PAGE>

<TABLE>
<S>      <C>                                                                       <C>
  26     Integrity testing of container/closure system to be used in the
         Octreother hot liquid production                                              17MJO99R

  27     DETERMINATION OF EXCIPIENTS IN REACTION VIALS FOR OCTREOTHER
         VALIDATION OF THE METHOD Addendum                                             19MJO00R

  28     OCTREOTHER CONSISTENCY RUNS OF ADAPTED PRODUCTION PROCESS.
         MICROBIOLOGICAL DATA                                                          24WGO00R

  29     Preliminary Stability Results SMT487 (90Y) Liquid                             27mjo97r

  30     Radiochemical Purity Determination of OctreoTher Using Different
         Integration Events                                                            32MJ099R

  31     OCTREOTHER FORMULATION REPORT                                               5061/14/1996

  32     DEVELOPMENT OF OCTREOTHER-90 KIT                                            5061/15/1995

  33     DOTA-TYR3-OCTREOTIDE ASSAY BY HPLC.
         VALIDATION OF METHOD                                                        5061/21/1996

  34     RADIOCHEMICAL PURITY OF 90Y-DOTA-TYR3-OCTREOTIDE.
         VALIDATION OF THE METHOD                                                    5061/22/1996

  35     INCORPORATION OF 90Y-DOTA-TYR3-OCTREOTIDE VALIDATION OF THE METHOD          5061/24/1996

  36     STABILITY 90Y-SMT487 FOR HOT-TOXICITY STUDY                                   07MJO97R

  37     Quality testing of Yttrium (90Y) chloride by means of incorporation
         assay into DOTA-Tyr3-Octreotide                                               12mjo02R

  38     Influence of the Alltech 1.0 ml Minivial 20/4000 on the incorporation
         capability of Y-90 to SMT 487 peptide                                         18ewe03r

  39     Close out report B220X project, validation status of OctreoTher
         facility                                                                     2465201001

  40     Extension of the OctreoTher production                                    Memo to File, E.
                                                                                     van Wensveen

  41     Identification of Impurities in gentisic acid and peroxide cured
         silicon tubing                                                                13MJO02R

  42     Air-tightness testing mepal container for Yttrium-OctreoTher
         solution shipments                                                           2132701003

  43     testing box 33 Multipack containing Yttrium-OctreoTher solution              2132701001
</TABLE>

                                       19

<PAGE>

                     TABLE 2. STANDARD OPERATING PROCEDURES

<TABLE>
<CAPTION>
Title document                                                               code
--------------                                                             --------
<S>                                                                        <C>
Octreother                                                                 D3-03925
Reactionmixture for Octreother bulk                                        D6-03925
Reactiemixture for Octreother                                              D7-03925
Dispensing set, solutions and dilutions, 10 - 25 ml, sterilized            E2-10504
Fiterset, Millipak 60, sterilized                                          E2-10561
tubingset Octreother, cel 0902.000 Compudil A, sterilized                  E2-11326
tubingset Octreother, cel 0902.000 diluter, sterilized                     E2-11328
tubingset Octreother, cel 0903.000, sterilized                             E2-11331
Filter, Pall, NOVASIP, C2PFRP1,                                            E2-11375
Tubingset, diluter Octreother, 3 flasks, sterilized                        E2-11407
tubingset, verdunner Octreother, sterilized                                E2-11412
Pumping set Octreother, cel 0903.000                                       E2-11413
Needle, pencilpoint, diam 1,2mm                                            E2-11418
Z-needle, pencilpoint, lengte 20x20x78mm                                   E2-11419
Curved needle, pencilpoint, diam 1,2mm, lengte 20x54mm                     E2-11421
Tubing set, bulkfluidreactionmixture, sterile                              E2-11441
Curved needle,pencilpoint, diam 1,2 mm, lengte 20x87 mm                    E2-11445
Curved needle,pencilpoint, diam 1,2 mm, lengte 28x57 mm                    E2-11446
Z-needle, pencilpoint, 20x20x78mm, passivated                              E2-11447
Curved needle, pencilpoint, 20x54mm, passivated                            E2-11448
Curved needle,pencilpoint, diam 1,2 mm, lengte 20x50 mm                    E2-11449
Dispensing set, sofiumchloride for octreother, gesteriliseerd              E2-11450
Curved needle, pencilpoint, 28x57mm, gepassiveerd                          E2-11456
Curved needle, pencilpoint, 20x87mm, gepassiveerd                          E2-11457
Dispensing set Octreother forunit cel 0903.000, gesteriliseerd             E2-11467
Filterset A Millipak 60, Pt-netted tubing                                  E2-11490
filterset B Millipak 60, Pt-netted tubing                                  E2-11491
Dispensing set, Pt-netted tubing                                           E2-11492
dispensingset, Pt-netted tubing                                            E2-11492
flask 2, assembleerd, Millipak 60, Pt-netted tubing                        E2-11493
flask 2, assembleerd, Millipak 60, Pt-netted tubing                        E2-11493
Dispensing set for kits, Pt-netted tubing                                  E2-12007
Lyophilization vial 10 ml, stopper FM157, clean                            E2-12198
Wing needle, diam 2,0mm,  lengte 20x280mm                                  E2-12336
transportcontainer Octreother                                              E3-11472
Certificate of analysis: Octreother                                        E4-11335
SPC Yttrium (Y90) SMT487, i.v.                                             E4-11373
Rubberstopper                                                              E6-10030
Rubberstopper                                                              N6-10856
Water for injecties, in bulk                                               E5-10114
Purified water                                                             E5-12300
Materials for the productie of octreother                                  E5-11408
Lyophilization vial 10 ml,                                                 E6-10009
Lyophilization stopper, DIAM 20 mm,  FM157,                                E6-10018
vial 100 ml, clean gesteriliseerd                                          E6-11303
vial 100ml, filled with nitrogen                                           E6-11304
Rubberstop, diam 32 mm, FM257, clean, sterile                              E6-11308
Needleprotector, rubber, 14 mm                                             E6-11394
Elution needle protector                                                   E6-10130
Octreother                                                                 F3-03925
Reactiemixture for octreother, bulk                                        F6-03925
</TABLE>

                                       20

<PAGE>

                     TABLE 2. STANDARD OPERATING PROCEDURES

<TABLE>
<CAPTION>
Title document                                                               code
--------------                                                             --------
<S>                                                                        <C>
Reactiemixture for voor Octreother                                         F7-03925
ring glassvial Octreother-Lab                                              G0-00095
ring Nensure P-2 flacon Octreotherlab                                      G0-00102
ring 10 ml lyophilization vial Octreotherlab                               G0-00105
ring for 100 ml flacon octreotherlab                                       G0-00114
Testset for visual inspection of vials in octreotherlab en radiopharmacy   G0-00147
Vial 500 ml Vacuum steriel                                                 N1-12015
Tubing, siliconubber, diam 6,0 x 10,0 mm                                   N2-10044
Tubing, siliconrubber, diam 4,0x7,0mm                                      N2-10459
Tubing, siliconrubber, diam 4,0 x 7,0 mm                                   N2-10459
Tubing, siliconrubber, diam 1,0x3,0mm                                      N2-10460
Filter millex                                                              N2-10825
Tubing, siliconrubber, diam 4,0 x 10,0 mm                                  N2-10462
Injection needle 18G, lengte 19 mm                                         N2-10561
Filter millipore, millipak 60 MPGL 06GH2                                   N2-10811
Filter hydrofoob ACRO 50                                                   N2-10826
Vail 250 ml                                                                N2-11429
Tubing, siliconrubber, 1,6 x 6,4 mm                                        N2-11435
Tubing, siliconrubber, 3,2 x 8,0 mm                                        N2-11436
Tubing 1,02 mm, diam  2,69 mm, lengte 3 m                                  N2-11476
Filter, Whatman, Polycap 36 SPF                                            N2-11508
Double tubingsett, 3,2 mm                                                  N2-11515
Double tubingset, 4,8 mm                                                   N2-11516
Curved needle, diam 0,9 x 1,2 mm, lengte 20 x 200 mm                       N2-11595
Threeway valve                                                             N2-11730
Tubing, siliconrubber, 2,38 x 4,0 mm                                       N2-11743
Tubing siliconrubber, 2,29x0,85x900mm                                      N2-11744
capsule, diam 32,5 mm,                                                     N2-11745
Filter, Pall, Novasip, C2PFRP1                                             N2-11775
Tubing, siliconrubber, diam. 1,6 x 4,8 mm                                  N2-11785
Vial 500ml                                                                 N2-11820
dispensingset octreother, cel 0903.000                                     N2-11852
Filter, Millex 0,22 ugm, SLGP 033 RS                                       N2-11855
Tubing, siliconrubber, diam 4,8 x 9,6 mm                                   N2-11858
Tubing, siliconrubber, diam 6,4 x 9,6 mm                                   N2-11859
Syringe                                                                    N2-11925
Tubing, PTFE, capilaire tubing                                             N2-11926
Wing needle, 18G x 1,5                                                     N2-11927
Syringe 1 ml luerlock H804                                                 N2-12035
Neo labbinders                                                             N2-12041
Tubing siliconenrubber 10 x 14                                             N2-12075
T-piece Diam, 6 MM P.P.                                                    N2-12081
Filter Millex SLFG 025 LS                                                  N2-12098
Connector Luer 0,8 female                                                  N2-12111
Connector Luer 1.6 male                                                    N2-12112
Connector luer 0,8 male                                                    N2-12113
Connector Luer 1,6 female                                                  N2-12115
Connector luer 3.2 Female                                                  N2-12117
Connector Luer 3.2 MALE                                                    N2-12118
Naald vleugel/beluchting 1.6 MM                                            N2-12119
T-part, polupropylene                                                      N2-11915
Beaker, plastic                                                            N3-11854
</TABLE>

                                       21

<PAGE>

                     TABLE 2. STANDARD OPERATING PROCEDURES

<TABLE>
<CAPTION>
Title document                                                               code
--------------                                                             --------
<S>                                                                        <C>
Demineralized water                                                        N5-70362
Ascorbic acid                                                              N5-70001
sodiumhydroxide,                                                           N5-70016
nitrogenf 99,98 % fluid                                                    N5-70120
GENTISIc acid                                                              N5-70128
Inositol                                                                   N5-70135
Water forr injections in vial, 1000 ml                                     N5-70261
sodiumchloride-solution 0,9% in vial 1000 ml                               N5-70267
DOTA-TYR3-octreotide                                                       N5-70415
Connector                                                                  N6-10158
lyophilizationstopper diam 20mm grey FM157                                 N6-10159
Needle, Z-vormig UTK                                                       N6-10177
Venapunction needle                                                        N6-10179
Lyophilization vial 10 ml                                                  N6-10217
Needle steel 316, diam 0,83x1,2mm, lengte 173mm                            N6-10247
Elution needle protector                                                   N6-10006
vail 100 ml,                                                               N6-11736
Rubberstopper, diam 32 mm, , FM257                                         N6-11737
capsule, aluminium, diam 20 mm                                             N6-11884
capsule, diam 32,5 mm,                                                     N6-11887
Yttrium chloride (Y90)                                                     N7-70429
Needle                                                                     N6-10248
Tubing set                                                                 P5-11407
dispensinglset, solutions, 10 - 25 ml, gesteriliseerd                      P2-10504
Filterrset, Millipak 60, gesteriliseerd                                    P2-10561
tubingset Octreother, cel 0902.000, Compudil A, gesteriliseerd             P2-11326
tubingset Octreother, cel 0902.000, diluter, gesteriliseerd                P2-11328
tubingset Octreother, cel 0903.000, gesteriliseerd                         P2-11331
tubingset, diluter octreother, 3 flasks, gesteriliseerd                    P2-11407
Tubingset diluetr octreother, gesteriliseerd                               P2-11412
Pumptubingset octreother, cel 0903.000                                     P2-11413
tubingset, bulk reactionmixture octreother, gesteriliseerd                 P2-11441
Z-needle, pencilpoint, 20x20x78mm, gepassiveerd                            P2-11447
Curved needle, pencilpoint, 20x54mm, gepassiveerd                          P2-11448
dispensingset sodiumchloride for octreother gesteriliseerd                 P2-11450
Curved needle, pencilpoint, 28x57mm, gepassiveerd                          P2-11456
Curved needle, pencilpoint, 20x87mm, gepassiveerd                          P2-11457
Materials for the production of octreother                                 P5-11408
Lyophilization stopper, DIAM 20 mm,  FM157,sterilized                      P6-10018
vial 100ml filled with nitrogen                                            P6-11304
Rubberstop, diam 32 mm, , FM257,                                           P6-11308
Visual inspection of octreother vials                                      W0-10364
Procedure to calculate the yttrium-90 amount to order                      W0-10436
Measurement of  radioactivity with an ionisatiecahmber with picoammeter    W1-10001
</TABLE>

                                       22

<PAGE>

                    TABLE 3. REGULATORY INFORMATION DOCUMENTS

<TABLE>
<CAPTION>
Number   Title
------   -----
<S>      <C>
  1      Yttrium (90Y) SMT 487 Clinical Trial Application Information
         Chemical and Pharmaceutical Data

  2      Yttrium (90Y) SMT 487 IND Information
         Manufacturing Description
</TABLE>

                                       23

<PAGE>

                          TABLE 4. ADDITIONAL DOCUMENTS

<TABLE>
<CAPTION>
Number   Title
------   -----
<S>      <C>
  1      Description of the lyophilization process

  2      Description of the equipment used in the manufacturing process
         for the Product

  3      Description of the Quality Control equipment used in the
         quality control methods of the Vials

  4      Description of the Quality Control equipment used in the
         quality controls methods of the Product
</TABLE>

                                       24

<PAGE>

B.2. Manufacture and Quality Control of the Vials (OctreoTher Reaction Vial)

Prior to commencing the manufacturing and quality control technology transfer at
the Petten Facility, MIP personnel must successfully complete Laboratory and
Radiation Safety Training conducted by Safety Personnel at the MALLINCKRODT
Petten site.

     B.2.1. Manufacturing of the Vials

MALLINCKRODT personnel will describe and demonstrate to MIP personnel the
manufacturing process for the OctreoTher Reaction Vial consistent with or
equivalent to GMPs at the MALLINCKRODT facility in Petten, The Netherlands. The
following services will be provided:

     -    a review of the Process Flow Sheet describing the manufacturing,
          ingredients, and materials needed in the manufacturing process;

     -    a review of the packaging;

     -    one demonstration of the preparation of the matrix solution, without
          the addition of the peptide SMT 487, by MALLINCKRODT personnel during
          the initial visit to Petten by MIP personnel. MIP has the right to
          request that MALLINCKRODT personnel perform one additional
          demonstration of the preparation of the matrix solution, without the
          addition of the peptide SMT 487, at a date and site to be determined
          after the initial visit to Petten by MIP personnel. In the event that
          this additional demonstration occurs, MIP shall pay MALLINKRODT'S
          expenses pursuant to Section 2.3;

     -    at least one but not more than two preparations of the matrix solution
          by MIP personnel with MALLINCKRODT personnel supervision during the
          initial visit to Petten by MIP personnel. MIP has the right to perform
          at least one but not more than two preparations of the matrix solution
          by MIP personnel with MALLINCKRODT

                                       25

<PAGE>

          personnel supervision at a date and site to be determined after the
          initial visit to Petten by MIP personnel. In the event that such
          additional activities occur, MIP shall pay MALLINKRODT'S expenses
          pursuant to Section 2.3;

     -    the parameters for the lyophilization cycle;

     -    discussion of the documents provided in Tables 1, 2, and 3 as they
          pertain to the OctreoTher Reaction Vial manufacturing, such as product
          specifications, batch records, stability studies, fill-finish, and the
          lyophilization cycle.

     B.2.2. Quality Control of Vials

MALLINCKRODT personnel will describe and demonstrate to MIP personnel the
quality control (QC) methods for the OctreoTher Reaction Vial consistent with or
equivalent to GMPs at the MALLINCKRODT facility in Petten, The Netherlands.
OctreoTher Reaction Vials from lot number 220930 will be used for this testing.
The following services will be provided:

     -    one demonstration of the QC methods for the ingredients by
          MALLINCKRODT personnel during the initial visit to Petten by MIP
          personnel. MIP has the right to request that MALLINCKRODT personnel
          perform one additional demonstration of the QC methods at a date and
          site to be determined after the initial visit to Petten by MIP
          personnel. In the event that this additional demonstration occurs, MIP
          shall pay MALLINKRODT'S expenses pursuant to Section 2.3;

     -    one demonstration of in-process testing by MALLINCKRODT personnel
          during the initial visit to Petten by MIP personnel. MIP has the right
          to request that MALLINCKRODT personnel perform one additional
          demonstration of in-process testing at a date and site to be
          determined after the initial visit to Petten by MIP personnel. In the
          event that this additional demonstration occurs, MIP shall pay
          MALLINKRODT'S expenses pursuant to Section 2.3;

                                       26
<PAGE>

     -    one demonstration of the QC methods for the Vial by MALLINCKRODT
          personnel during the initial visit to Petten by MIP personnel. MIP has
          the right to request that MALLINCKRODT personnel perform one
          additional demonstration of the QC methods for the Vial at a date and
          site to be determined after the initial visit to Petten by MIP
          personnel. In the event that this additional demonstration occurs, MIP
          shall pay MALLINKRODT'S expenses pursuant to Section 2.3;

     -    at least one but not more than two completions by MIP personnel of the
          QC methods for the ingredients, in-process testing, and the Vial with
          MALLINCKRODT personnel supervision during the initial visit to Petten
          by MIP personnel. MIP has the right to perform at least one but not
          more than two completions of the QC methods for the ingredients,
          in-process testing, and the Vial with MALLINCKRODT personnel
          supervision at a date and site to be determined after the initial
          visit to Petten by MIP personnel. In the event that such additional
          activities occur, MIP shall pay MALLINKRODT'S expenses pursuant to
          Section 2.3;

     -    discussion of the documents provided in Tables 1, 2, and 3 as they
          pertain to OctreoTher Reaction Vial quality control.

B.3. Manufacture and Quality Control of the Product (OctreoTher Hot Liquid)

     B.3.1. Manufacturing of the Product

MALLINCKRODT personnel will describe and demonstrate to MIP personnel the
manufacturing process for the Product consistent with or equivalent to GMPs at
the MALLINCKRODT facility in Petten, The Netherlands. OctreoTher Reaction Vials
from lot number 220930 will be used for the manufacturing of the Product. The
following services will be provided:

                                       27

<PAGE>

     -    a review of the Process Flow Sheet describing the manufacturing,
          ingredients, and materials needed in the manufacturing process;

     -    a review of the packaging;

     -    one demonstration of the preparation of the OctreoTher Hot Liquid
          without Y-90 by MALLINCKRODT personnel during the initial visit to
          Petten by MIP personnel. MIP has the right to request that
          MALLINCKRODT personnel perform one demonstration of the OctreoTher Hot
          Liquid without Y-90 at a date and site to be determined after the
          initial visit to Petten by MIP personnel. In the event that this
          additional demonstration occurs, MIP shall pay MALLINKRODT'S expenses
          pursuant to Section 2.3;

     -    one demonstration of the preparation of the OctreoTher Hot Liquid with
          Y-90 by MALLINCKRODT personnel during the initial visit to Petten by
          MIP personnel. MIP has the right to request that MALLINCKRODT
          personnel perform one additional demonstration of the OctreoTher Hot
          Liquid with Y-90 at a date and site to be determined after the initial
          visit to Petten by MIP personnel. In the event that this additional
          demonstrations occur, MIP shall pay MALLINKRODT'S expenses pursuant to
          Section 2.3;

     -    one preparation of the OctreoTher Hot Liquid without Y-90 by MIP
          personnel with MALLINCKRODT personnel supervision during the initial
          visit to Petten by MIP personnel. MIP has the right to perform one
          preparation of the OctreoTher Hot Liquid without Y-90 by MIP personnel
          with MALLINCKRODT personnel supervision at a date and site to be
          determined after the initial visit to Petten by MIP personnel. In the
          event that such additional activities occur, MIP shall pay
          MALLINKRODT'S expenses pursuant to Section 2.3;

                                       28

<PAGE>

     -    one preparation of the OctreoTher Hot Liquid with Y-90 by MIP
          personnel with MALLINCKRODT personnel supervision during the initial
          visit to Petten by MIP personnel. MIP has the right to perform one
          preparation of the OctreoTher Hot Liquid with Y-90 by MIP personnel
          with MALLINCKRODT personnel supervision at a date and site to be
          determined after the initial visit to Petten by MIP personnel. In the
          event that such additional demonstrations occur, MIP shall pay
          MALLINKRODT'S expenses pursuant to Section 2.3;

     -    discussion of the documents provided in Tables 1, 2, and 3 as they
          pertain to the OctreoTher Hot Liquid manufacturing, such as product
          specifications, batch records, and stability studies.

     B.3.2. Quality Control of Product

MALLINCKRODT personnel will describe and demonstrate to MIP personnel the
quality control (QC) methods for the OctreoTher Hot Liquid consistent with or
equivalent to GMPs at the MALLINCKRODT facility in Petten, The Netherlands. The
following services will be provided:

     -    one demonstration of in-process testing by MALLINCKRODT personnel
          during the initial visit to Petten by MIP personnel. MIP has the right
          to request that MALLINCKRODT personnel perform one additional
          demonstration of in-process testing at a date and site to be
          determined after the initial visit to Petten by MIP personnel. In the
          event that this additional demonstration occurs, MIP shall pay
          MALLINKRODT'S expenses pursuant to Section 2.3;

     -    one demonstration of the QC methods for the Product by MALLINCKRODT
          personnel, preferably on the Product manufactured by MALLINCKRODT in
          Section B.3.1 during the initial visit to Petten by MIP personnel. MIP
          has the right to request

                                       29

<PAGE>

          that MALLINCKRODT personnel perform one additional demonstration of
          the QC methods for the Product at a date and site to be determined
          after the initial visit to Petten by MIP personnel. In the event that
          this additional demonstration occurs, MIP shall pay MALLINKRODT'S
          expenses pursuant to Section 2.3;

     -    at least one but not more than two completions by MIP personnel of the
          QC methods for in-process testing and the Product, preferably on the
          Product produced by MIP in Section B.3.1, with MALLINCKRODT personnel
          supervision during the initial visit to Petten by MIP personnel. MIP
          has the right to perform at least one but not more than two
          completions by MIP personnel of the QC methods for in-process testing
          and the Product with MALLINCKRODT personnel supervision at a date and
          site to be determined after the initial visit to Petten by MIP
          personnel. In the event that such additional activities occur, MIP
          shall pay MALLINKRODT'S expenses pursuant to Section 2.3;

     -    discussion of the documents provided in Tables 1, 2, and 3 as they
          pertain to OctreoTher Hot Liquid quality control.

B.4. Response to Inquires Concerning the Technology

MALLINCKRODT personnel will be available to provide responses or clarification
to inquiries from MIP concerning the Technology during the course of the
transfer of the Technology as described in Section 2.3.

B.5. Equivalency Testing of the Product (OctreoTher Hot Liquid)

MALLINCKRODT and MIP personnel will conduct equivalency testing on the
OctreoTher Hot Liquid. Equivalency testing will consist of MALLINCKRODT and MIP
independently conducting quality control (QC) testing of the Product as defined
by the specifications in Section

                                       30

<PAGE>

5.3.1 of the Yttrium ((90)Y) SMT 487 IND Information Manufacturing Description
attached to this Agreement as EXHIBIT F. The OctreoTher Hot Liquid will be
manufactured consistent with or equivalent to GMPs by either MALLINCKRODT or MIP
as specified below. The following services will be provided:

     -    MALLINCKRODT will prepare one manufacturing preparation of the
          OctreoTher Hot Liquid sufficient to provide finished Product for QC
          testing by both MALLINCKRODT and MIP;

     -    MALLINCKRODT will ship to MIP the required vials of Product necessary
          to perform the QC testing;

     -    On the same date, MALLINCKRODT and MIP will independently perform the
          QC tests and MALLINCKRODT will inform MIP of its results.

     -    MALLINCKRODT will receive from MIP one but not more than two
          manufacturing preparations of the OctreoTher Hot Liquid manufactured
          by MIP;

     -    On the same date, MALLINCKRODT and MIP will independently perform the
          QC tests and MALLINCKRODT will inform MIP of its results.

                                       31
<PAGE>

                                    EXHIBIT C

               CERTIFICATION OF COMPLETION OF TECHNOLOGY TRANSFER

MALLINCKRODT INC. hereby certifies that it has completed its Technology transfer
obligations under that certain Agreement, dated as of ____________, 2006,
between MALLINCKRODT INC. and MOLECULAR INSIGHT PHARMACEUTICALS, INC.

MALLINCKRODT INC.

By:
    ---------------------------------
Title:
       ------------------------------
Date:
      -------------------------------

                                       32

<PAGE>

                                    EXHIBIT D

Specifications for the OctreoTher SMT 487 Reaction Vial are as follows:

<TABLE>
<CAPTION>
            TEST                               LIMIT
            ----                               -----
<S>                            <C>
Appearance                     clear and no visual impurities
pH                             4.0 - 5.0
Sterility                      sterile
Endotoxins                     < or = 20 EU/vial
Ascorbic acid                  64.0 - 78.2 mg/vial
Inositol                       36.0 - 44.0 mg/vial
Radiochemical purity, 15 min   > or = 90%
Radiochemical purity, 6 h      > or = 90%
(90)Y-Incorporation            > or = 99.5%
SMT 487                        72.0 - 88.0 ug/vial
Uniformity SMT 487 content     10 vials within 85 - 115% (n=10) or
                               < or = 1 of 30 out of 85 - 115%, but all
                               within 75 - 125%
Gentisic acid                  14.4 - 17.6 mg/vial
Water content                  < or = 5%
Identity                       comply with test
</TABLE>

                                       33

<PAGE>

                                    EXHIBIT E

The overall work plan and timeline for the Transfer of Technology is as follows:

<TABLE>
<CAPTION>
                                                                 Month 1   Month 2   Month 3    Month 4    Month 5     Month 6
                                                                   Days      Days      Days      Days        Days        Days
TASK NAME                                                         1 - 30   31 - 60   61 - 90   91 - 120   121 - 150   151 - 180
---------                                                        -------   -------   -------   --------   ---------   ---------
<S>                                                              <C>       <C>       <C>       <C>        <C>         <C>
CONTRACT EXECUTION
   Mallinckrodt & MIP Execute Contract
   Mallinckrodt Receives Initial Payment at Contract Execution
   Mallinckrodt Invoices MIP and Receives 50% Payment for
      OctreoTher Vials
   Mallinckrodt Initiates SOP Translation per MIP Instructions
COMMENCEMENT OF TECHNOLOGY TRANSFER
   Mallinckrodt Transmits R&D and Regulatory Documents to MIP
   Mallinckrodt Transmits First Set of Translated SOPs to MIP
   Mallinckrodt Invoices MIP for Payment due upon Commencement
      of Technology transfer
   Mallinckrodt Ships OctreoTher Vials to MIP per Their
      Instructions
   Mallinckrodt Invoices MIP for Remaining 50% Payment due for
      OctreoTher Vials
   Mallinckrodt Receives Above Two Payments Prior to On-Site
      Technology Transfer
TRANSFER OF TECHNOLOGY AT MALLINCKRODT PETTEN FACILITY
   Mallinckrodt Provides Services per Exhibit B
MALLINCKRODT TECHNICAL AVAILABILITY
   Mallinckrodt Provides Services per Exhibit B
TRANSFER OF TECHNOLOGY AT MIP DESIGNATED FACILITY (IF
   REQUESTED)
   Mallinckrodt Provides Services per Exhibit B
EQUIVALENCY TESTING
   Mallinckrodt Provides Services per Exhibit B
TECHNOLOGY TRANSFER COMPLETION
   Mallinckrodt Sign-Off of Certificate of Completion
   Mallinckrodt Invoices for and Receives Payment for
      Completion of Technology Transfer
</TABLE>

                                       34

<PAGE>

                                    EXHIBIT F

Specifications for Yttrium (90Y) SMT 487 (OctreoTher Hot Liquid) are as follows:

<TABLE>
<CAPTION>
           TEST                                  LIMIT
           ----                                  -----
<S>                         <C>
Appearance                  Clear, colourless, or slightly yellow solution
(90)Y-Incorporation         > or = 99.3%
Radiochemical purity        > or = 90%
Radioactive concentration   51.6 Bq/ml +/- 10% (1.4 mCi/ml +/- 10%)
pH                          4.0 - 5.0
Endotoxins                  < or = 0.2 EU/vial (parametric release)
Sterility                   sterile (parametric release)
</TABLE>

                                       35

<PAGE>

                                    EXHIBIT G

Below is a list of MALLINCKRODT competitors.

     Bracco
     Bristol-Myers Squibb
     Cardinal Health, Inc.
     GE Healthcare Division of the General Electric Company
     Schering AG

                                       36<PAGE>

                                                                   EXHIBIT 10.31

              LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the "Agreement"),
effective as of January 15, 2007 (the "Effective Date"), is entered into by and
between BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, a German corporation having
its principal place of business at Muellerstrasse 178, 13353 Berlin, Germany
("Schering"), and MOLECULAR INSIGHT PHARMACEUTICALS, INC., a Delaware
corporation having its principal place of business at 160 Second Street,
Cambridge, Massachusetts 02142, USA ("Molecular Insight"). Schering and
Molecular Insight both may be referred to herein individually as a "Party" and
collectively as the "Parties".

                                   BACKGROUND

WHEREAS:

A.   Schering owns certain intellectual property rights relating to I-131
     labeled ZK-BA, a new class of proprietary benzamide compounds highly
     accumulating in metastatic melanoma, that may be of use in the field of
     oncology, in particular for the diagnosis and treatment of metastatic
     melanoma.

B.   Molecular Insight desires to obtain from Schering an exclusive, worldwide
     license in such intellectual property rights to make, use, sell, offer for
     sale, and import pharmaceutical products; and

C.   Schering is willing to grant such license to Molecular Insight on the terms
     and conditions hereinafter set forth.

NOW, THEREFORE, the Parties hereby agree as follows:

1. DEFINITIONS

     As used in this Agreement, the following terms shall have the meanings
indicated:

     1.1  "Affiliate" means, with respect to a Party, any person, corporation,
          firm, joint venture or other entity which, directly or indirectly,
          through one or more intermediates, controls, is controlled by or is
          under common control with such Party. As used in this definition,
          "control" means possession of the power to direct or cause the
          direction of the management and policies of an entity, whether through
          the ownership of the outstanding voting securities or by contract or
          otherwise.

     1.2  "Agreement" shall mean this Agreement.

     1.3  "Business Day" means any day that is not a Saturday, a Sunday or other
          day on which banks are required or authorized by law to be closed in
          Berlin, Germany or Cambridge, MA, USA.

<PAGE>

     1.4  "Clinical Trial" means a Phase I Clinical Trial, Phase II Clinical
          Trial or a Phase III Clinical Trial utilizing the Compounds in the
          Field.

     1.5  "Commercialization" and "Commercialize" shall refer to all activities
          undertaken relating to the manufacture, pre-marketing, marketing,
          distribution and sale of a Product, and the process of
          Commercialization, respectively.

     1.6  "Commercially Reasonable Efforts" means the level of endeavor which a
          company in the prescription pharmaceutical industry comparable in size
          to Molecular Insight and active in development and commercialization
          of pharmaceutical compositions would ordinarily expend for a product
          with an equivalent sales and profit potential to a relevant Product.

     1.7  "Compounds" means the ZK-BA compounds and derivatives thereof, a new
          class of benzamide compounds highly accumulating in metastatic
          melanoma, that may be of use in the field of oncology, and in
          particular for the diagnosis and treatment of metastatic melanoma as
          more fully described in ANNEX 1.7 attached hereto and made a part
          hereof.

     1.8  "Confidential Information" means all information belonging to or in
          the possession of the Parties and their Affiliates which they consider
          confidential including, without limitation, information concerning the
          study, discovery, design, development, manufacture, formulation,
          extraction, compounding, mixing, processing, testing, control,
          preservation, storage, finishing, packing, packaging, use,
          administration, distribution, sale, reimbursement and/or marketing of
          pharmaceutical products or compounds and potential products or
          compounds, and shall further include, without limitation, all
          information marked "confidential" by a Party, data from and
          methodology of pre-clinical and clinical studies, the contents of any
          submissions to regulatory authorities worldwide, marketing plans or
          computer hardware and software systems and designs and plans for same.
          Confidential Information may be conveyed in written, graphical,
          physical or oral form

     1.9  "Control" or "Controlled" shall mean possession of the ability to
          grant the licenses or sublicenses as provided for herein without
          violating the terms of any agreement or other arrangement with any
          Third Party.

     1.10 "Development" means all activities, or the performance thereof,
          relating to preclinical development and clinical development, as are
          customary in the pharmaceutical industry as part of the process of
          obtaining Regulatory Approval.

     1.11 "Development Plan" has the meaning contained in Section 6.1.

     1.12 "Drug Approval" means the regulatory approval required before
          commercial sale or use of a Product as a drug in a regulatory
          jurisdiction, including, for purposes of Regulatory Approval in the
          US, a New Drug or a Biological License and all supplements filed
          pursuant to the requirements of the FDA (including all documents, data
          and other information concerning a Product that are necessary for, or
          included in, FDA approval to market a Product) and, for purposes of
          Regulatory Approval in the EU, all and any regulatory approval by the
          EMEA or any other applicable national regulatory authority.

                                        2

<PAGE>

     1.13 "Effective Date" shall have the meaning set forth at the head of this
          Agreement.

     1.14 "EMEA" means the European Medicines Evaluation Agency, or any
          successor agency with responsibility for regulating the development,
          manufacture and sale of human pharmaceutical products.

     1.15 "EU" means the countries of the European Union, as constituted from
          time to time.

     1.16 "FDA" means the United States Food and Drug Administration of the
          Department of Health and Human Services, or any successor agency with
          responsibility for regulating the development, manufacture and sale of
          human pharmaceutical products.

     1.17 "FDA Equivalent" means the equivalent of FDA, but in a legal
          jurisdiction other than the US.

     1.18 "Field" means any use in the diagnosis, cure, mitigation, treatment or
          prevention of disease in human beings in the field of oncology.

     1.19 "Final Milestone Payment" has the meaning contained in Section 4.2.

     1.20 "First Commercial Sale" means the date Molecular Insight or an
          Affiliate or Sublicensee of Molecular Insight first sells, or
          otherwise disposes of, commercially to a third party, a Product
          pursuant to a Regulatory Approval.

     1.21 "GCP" means the Good Clinical Practices guidelines published by FDA,
          and published standards of FDA (or other standards of FDA that are
          generally recognized within the United States pharmaceutical industry)
          that relate to the conduct of clinical studies in humans. GCP also
          includes similar standards, guidelines and regulations promulgated or
          otherwise required by the European Commission, and published standards
          of the European Commission (or other standards of the European
          Commission that are generally recognized within the European
          pharmaceutical industry), including the ICH Harmonised Tripartite
          Guideline for Good Clinical Practice, as amended from time to time.

     1.22 "GLP" means the Good Laboratory Practices Regulations promulgated by
          FDA, as they may be amended from time to time. GLP also includes
          published standards of FDA (or other standards of FDA that are
          generally recognized within the United States pharmaceutical industry)
          that relate to the conduct of preclinical studies in animals. GLP also
          includes similar standards, guidelines and regulations promulgated or
          otherwise required by the European Commission, and published standards
          of the European Commission (and other standards of the European
          Commission that are generally recognized within the European
          pharmaceutical industry), including Council Directive 2001/83/EC, as
          amended from time to time.

     1.23 "GMP" means the Good Manufacturing Practices regulations and General
          Biologics Products Standards promulgated by FDA, as they may be
          amended from time to time. GMP also includes published standards of
          FDA (or other

                                        3

<PAGE>

          standards of FDA that are generally recognized within the United
          States pharmaceutical industry) that relate to the testing,
          manufacturing, processing, packaging, holding or distribution of drug
          or biologic drug substances and finished drugs or biologics. GMP also
          includes similar standards, guidelines and regulations promulgated or
          otherwise required by the European Commission, and published standards
          of the European Commission (and other standards of the European
          Commission that are generally recognized within the European
          pharmaceutical industry), including the Guide to Good Manufacturing
          Practices for Medicinal Products as promulgated under European
          Directive 91/356/EEC, as amended from time to time.

     1.24 "IND" means an Investigational New Drug application filed with FDA
          pursuant to 21 CFR 312.1 et seq., as such regulations may be amended
          from time to time.

     1.25 "IND Equivalent" means the equivalent of an IND, but in a legal
          jurisdiction other than the US.

     1.26 "Know-How" means Information relating to the Technology in the Field
          and the development of Products in the Field, including, but not
          limited to, inventions, techniques, practices, methods, knowledge,
          know-how, skill, trade secrets, experience and test data (including
          pharmacological, toxicological, preclinical and clinical test data);
          data, records and information derived from research, preclinical
          development and clinical development; regulatory submissions, adverse
          reactions, CMC/process development, analytical and quality control
          data, and Commercialization, marketing, pricing, distribution, cost,
          sales and manufacturing data or descriptions and provided to Molecular
          Insight as set forth in Annex 1.39.

     1.27 "Technology" shall mean benzamide compounds highly accumulating in
          metastatic melanoma controlled by Schering.

     1.28 "Molecular Insight Intellectual Property" means Molecular Insight
          Patents and Molecular Insight Know-How.

     1.29 "NDA" means a New Drug Application filed with the FDA, for approval by
          such agency for the sale of Products in the US pursuant to 21 CFR 200
          et seq., as such regulations may be amended from time to time.

     1.30 "NDA Equivalent" means the equivalent of an NDA, but in a legal
          jurisdiction other than the US.

     1.31 "Net Sales" means with respect to any Product, the gross revenues
          received by Molecular Insight or its Affiliates or Sublicensees or
          distributors from worldwide sales of such Product, less deductions
          for: (a) transportation charges, including insurance actually paid;
          (b) sales and excise taxes and duties paid or allowed by a selling
          party and any other governmental charges imposed upon the production,
          inspection, use or sale of such Product; (c) any distributors fees,
          rebates or allowances, quantity or cash discounts, chargebacks, or
          fees actually granted in the ordinary course of business; (d)
          allowances or credits to customers, not in excess of the selling price
          of the Product, on account of governmental requirements, rejection,
          outdating or return of such Product. For the purpose of

                                        4

<PAGE>

          calculating Molecular Insight's Net Sales, the Parties recognize that
          (i) Molecular Insight's customers may include parties in the chain of
          commerce who enter into agreements with Molecular Insight as to price
          even though legal title to the Product does not pass directly from
          Molecular Insight to such customers, and even though payment for such
          Product is not made by such customers to Molecular Insight, and (ii)
          in such cases, chargebacks paid by Molecular Insight to or through a
          Third Party (such as a wholesaler) can be deducted by Molecular
          Insight from gross revenues in order to calculate Molecular Insight's
          Net Sales. Sales between Molecular Insight and Affiliates shall be
          excluded from the computation of Net Sales, except where such entities
          are end users in which case Net Sales shall include Net Sales to such
          entities; provided however, if such entities are using such Products
          solely for research or clinical testing purposes, indigent or other
          public support programs, then such sales between Molecular Insight and
          Affiliates shall be excluded from the computation of Net Sales.

          Upon the sale or other disposal of a Product other than in a bona fide
          arms length transaction exclusively for money or upon any use of a
          Product for purposes which do not result in a disposal of that Product
          in consideration of sales revenue customary in the country of use that
          sale, other disposal or use shall be deemed to constitute a sale at
          the relevant open market price in the country in which the sale, other
          disposal or use occurs, or, if that price is not ascertainable, a
          reasonable price assessed on an arms length basis for the goods or
          services provided in exchange of the supply.

     1.32 "Patents" means: (i) any United States and foreign patent
          applications and patents; (ii) any national, regional and
          international patent applications filed from patent applications and
          patents included in (i), including any divisional and continuation
          applications of the patent applications and patents included in (i)
          and any continuation-in-part applications to the extent dominated by
          patent applications and patents included in (i); (iii) any and all
          patents that have issued or in the future issue from patent
          applications included in (i) and (ii); and (iv) any and all extensions
          or restorations by existing or future extension or restoration
          mechanisms, including substitutions, reexaminations, revalidations,
          reissues, renewals, and extensions thereof.

     1.33 "Phase I Clinical Trials" has the meaning described in 21 CFR 300 et
          seq.

     1.34 "Phase II Clinical Trials" has the meaning described in 21 CFR 300 et
          seq.

     1.35 "Phase III Clinical Trials" has the meaning described in 21 CFR 300 et
          seq. or such other pivotal clinical trial that will serve as a basis
          for FDA approval.

     1.36 "Product" means any pharmaceutical product the manufacture, use, sale,
          offer for sale, or import of which would infringe a Valid Claim of
          Schering Patents in the absence of a license.

     1.37 "Regulatory Approval" means any approval, product and/or establishment
          license, registration or authorization of any federal, state or local
          regulatory agency, department, bureau or other governmental entity,
          necessary for the commercial manufacture, use, storage, import,
          export, transport, commercialization or sale of a Product in a
          regulatory jurisdiction.

                                        5

<PAGE>

     1.38 "Schering Intellectual Property" means Schering Know-How and Schering
          Patents.

     1.39 "Schering Know-How" means Know-How within the control of Schering as
          of the Effective Date relating to the development of Products as
          contained in the documentation listed in ANNEX 1.39, excluding
          Schering's know-how in relation to the administration of the Compounds
          and the use of blood-supply modulators to reduce eye uptake in order
          to minimize potential side effects of the Compounds. Notwithstanding
          anything herein to the contrary, Schering Know-How shall exclude
          Schering Patents.

     1.40 "Schering Patents" means the patents and patent applications listed in
          ANNEX 1.40.

     1.41 "Sublicensee" shall mean a Third Party (except an Affiliate) to whom
          Molecular Insight has granted a sublicense to make, import, use, sell,
          offer for sale Products in the Territory.

     1.42 "Territory" shall mean all countries of the world.

     1.43 "Third Party" means any entity other than Schering or Molecular
          Insight and its respective Affiliates.

     1.44 "US" means the United States of America and its territories and
          commonwealths, including, without limitation, the Commonwealth of
          Puerto Rico.

     1.45 "Valid Claim" means a claim of (a) any unexpired Patent that has not
          been withdrawn, canceled or disclaimed nor held to be invalid or
          unenforceable by a court or tribunal of competent jurisdiction in an
          unappealed or unappealable decision or, (b) of any pending patent
          application, that has not been finally rejected in an unappealed or
          unappealable decision by the relevant patent office or court.

2. LICENSE GRANTS AND CONVEYANCE OF MATERIALS

     2.1 Exclusive License to Molecular Insight. Subject to the terms and
conditions of this Agreement, Schering hereby grants to Molecular Insight an
exclusive (even as to Schering) worldwide, royalty-bearing license under the
Schering Patents and Schering Know-How to make, use, sell, offer to sell and
import Products in the Field in the Territory. Such licenses shall include the
right to grant sublicenses under the Schering Intellectual Property, subject to
the provisions of Section 2.3.

     2.2 Grant of Option. Subject to the filing of a patent application by
Schering in relation to the administration of Compounds and the use of
blood-supply modulators to reduce eye uptake in order to minimize potential side
effects of the Compounds (such intellectual property rights collectively herein
referred to as "Eye Technology"), Schering hereby grants to Molecular Insight an
Option to obtain a non-exclusive license to the Eye Technology in the Field at
fair market value. Molecular Insight may exercise the Option within four (4)
months after Schering notifies Molecular Insight in writing that the Eye
Technology patent application has been filed ("Option Period"). During the
Option Period, Schering grants Molecular Insight a non-

                                       6

<PAGE>

exclusive license under the Eye Technology for the purpose of evaluation and
research only.

     2.3 Sublicenses. Subject to the terms and conditions of this Agreement,
Molecular Insight shall have the right to sublicense the rights granted in
Section 2.1 above. Each such sublicense shall be consistent with all the terms
and conditions of this Agreement. Molecular Insight shall remain responsible to
Schering for all of each such Sublicensee's applicable financial and other
obligations under each sublicense.

     2.4 No Further Rights. Only the licenses granted pursuant to the express
terms of this Agreement shall be of any legal force or effect. No other license
rights shall be granted or created by implication, estoppel or otherwise.

     2.5 Transfer of Schering Know-How. Schering undertakes to physically
transfer the items described in ANNEX 1.39 within 15 days of the effective date
of this Agreement to Molecular Insight at its address set forth above.

     2.6 Conveyance of Materials. Within thirty (30) days after the Effective
Date, Schering will transfer to Molecular Insight the materials in relation to
the Schering Patent, including as examples benzamide compound samples and
lyophilized vials as listed in ANNEX 2.6 to this Agreement, which are in
Schering's possession on the Effective Date.. Delivery shall be FOB Schering AG
or any other location at which Schering stores such materials, but will be,
otherwise, free of additional charge. Schering will provide the materials to
Molecular Insight without warranty of quality or fitness for a particular
purpose or any other warranty, express or implied.

3. CONSIDERATION

     3.1 Up-front Payment. In partial consideration of the rights granted to it
by Schering under this Agreement, Molecular Insight shall pay to Schering an
up-front fee in the amount of one million US dollars (USD$1,000,000) upon the
Effective Date. The said up-front payment will be unconditional and as such
shall not be subject to any offset, credit, reduction or repayment for any
reason whatsoever, whether provided for in this Agreement or not.

     3.2 Milestone Payments. Upon the occurrence of the relevant events
specified below with respect to each Product, Molecular Insight shall pay to
Schering the following amounts:

<TABLE>
<CAPTION>
                        Milestone                              Amount
                        ---------                              ------
<S>                                                         <C>
Commencement of Phase II Clinical Trial                     USD   **
Commencement of Phase III Clinical Trial                    USD   **
Receipt of first Drug Approval for marketing of a Product
   from FDA or FDA Equivalent (the "Final Milestone
   Payment")                                                USD   **
</TABLE>

     A Clinical Trial will be deemed to have commenced upon the dosing of the
first patient.

     The Final Milestone Payment is payable in   **  installments: The first
installment in the amount of      **      US dollars (USD     **    ) shall be
paid promptly after the first Drug Approval of a Product. The remaining  **
   **    US dollars (USD     **    ) are payable in

                                        7

                       *Confidential Treatment Requested*
<PAGE>

       **      installments starting three (3) months after the date of the
first Drug Approval for marketing of a Product.

     3.3 Royalties.

          3.3.1 Royalty on Net Sales. In partial consideration for the license
granted hereunder, Molecular Insight shall pay to Schering royalties for the
sale of Products, on a country-by-country basis, for a period from the date of
First Commercial Sale of a particular Product until the later of the expiration
of the last to expire Patent containing a Valid Claim or ten (10) years from the
date of First Commercial Sale.

          3.3.2 Royalty Rates. The royalty rates payable by Molecular Insight on
Net Sales of Products are as follows:

<TABLE>
<CAPTION>
                                Net Sales                                   Rate
                                ---------                                   ----
<S>                                                                         <C>
Sales of less than USD      **                                              **%
Sales equal or greater than USD     **      but less than USD      **       **%
Sales equal or greater than USD     **                                      **%
</TABLE>

4. PAYMENT

     4.1 Royalty Reports and Payments. Molecular Insight shall make royalty
payments to Schering within sixty (60) days after the end of each calendar
quarter in which Net Sales occurred. A report summarizing the Net Sales of each
Product during the relevant quarter on a country-by-country basis shall be
delivered to Schering within sixty (60) days following the end of each calendar
quarter for which royalties are due.

     4.2 Payments; Interest. Any payments due under this Agreement shall be due
on such date as specified in this Agreement and, in the event such date is not a
Business Day, then the next succeeding Business Day. Any failure by Molecular
Insight to make a payment within ten (10) Business Days after the date when due
shall obligate Molecular Insight to pay computed interest, the interest period
commencing on the due date and ending on the payment date, to Schering at a rate
per annum equal to the EURIBOR or USD LIBOR, as the case may be (according to
the underlying payment due), for one month quoted on the due date by the
European Central Bank plus a premium of three percent (3%). The interest rate
shall be adjusted monthly and interest shall be compounded monthly in arrears.
In addition, interest shall be computed on the basis of a 360 day year actual
days elapsed, and shall be due and payable on the tender of the underlying
principal payment.

     4.3 Taxes. Schering shall pay any and all taxes levied on account of all
payments it receives under this Agreement. If laws or regulations require that
taxes be withheld, Molecular Insight will (a) deduct those taxes from the
remittable payment, (b) timely pay the taxes to the proper taxing authority, and
(c) send proof of payment to Schering within thirty (30) days of receipt of
confirmation of payment from the relevant taxing authority. Molecular Insight
agrees to make reasonable efforts to minimize such taxes to Schering. If
Molecular Insight is so required then Schering and Molecular Insight shall
co-operate in all respects and take reasonable steps to lawfully avoid the
making of any such deductions.

     4.4 Payment Currency. All payments due hereunder will be paid to Schering
in US Dollars. All payments shall be paid by wire transfer of immediately
available funds to an account

                                        8

                       *Confidential Treatment Requested*
<PAGE>

at a commercial bank designated by Schering at least ten (10) Business Days
before payment is due. Where payments are based on Net Sales in countries other
than in the USA, the amount of such payments expressed in the currency of each
country shall be converted into US Dollar at the exchange rate of the last
Business Day of the applicable calendar quarter. The applicable exchange rate
will be the 12PM Buying Rates published by the Federal Reserve Bank of New York
on REUTERS screen (FEDSPOT). If no 12PM Buying Rate is determined for the
relevant currency, the Parties shall agree upon another reference rate.

     4.5 Records of Revenues. Molecular Insight shall keep for five (5) years
from the date of each payment of royalties complete and accurate records of
sales by Molecular Insight of each Product in sufficient detail to allow the
accruing royalties to be determined accurately. Schering shall have the right
for a period of five (5) years after receiving any report or statement with
respect to royalties due and payable to appoint at its expense an independent
certified public accountant reasonably acceptable to Molecular Insight to
inspect the relevant records of Molecular Insight to verify such report or
statement. Molecular Insight shall make its records available for inspection by
such independent certified public accountant during regular business hours at
such place or places where such records are customarily kept, upon reasonable
notice from Schering, to verify the accuracy of the reports and payments. Such
inspection right shall not be exercised more than once in any calendar year nor
more than once with respect to sales in any given period. The failure of
Schering to request verification of any report or statement during said
three-year period shall be considered acceptance of the accuracy of such report,
and Molecular Insight shall have no obligation to maintain records pertaining to
such report or statement beyond said three-year period. The findings of each
inspection, if any, shall be binding on both parties.

Schering shall bear its own costs related to such audit; provided, that for any
underpayments greater than five percent (5%) by Molecular Insight, Molecular
Insight shall pay Schering the amount of underpayment, interest as provided for
in Section 4.2 from the time the amount was due and Schering's out-of-pocket
expenses. For any underpayments less than five percent (5%) by Molecular Insight
found under this Section 5.5(a), Molecular Insight shall pay Schering the amount
of such underpayment. Any overpayments by Molecular Insight will, at Schering's
option, be refunded to Molecular Insight or credited to future royalties. Any
records or accounting information received from Molecular Insight shall be
confidential information for purposes of Sections 5.1 and 5.2. Results of any
such audit shall be provided to both Parties and shall be confidential
information for purposes of Sections 5.1 and 5.2.

5. CONFIDENTIALITY

     5.1 Confidential Information. Except as expressly provided herein, the
Parties agree that, for the term of this Agreement and for ten (10) years
thereafter, the receiving Party shall keep confidential and shall not publish or
otherwise disclose and shall not use for any purpose except for the purposes
contemplated by this Agreement, any Information furnished to it by the
disclosing Party hereto pursuant to this Agreement, except that to the extent
that it can be established by the receiving Party by competent proof that such
Information:

          5.1.1 is or becomes public or available to the general public
otherwise than through the act or default of the receiving Party;

          5.1.2 is obtained by the receiving Party from a Third Party who is not
subject to an obligation of confidentiality or non-use owed to the disclosing
Party;

          5.1.3 is previously known to the receiving Party prior to disclosure
to the

                                        9

<PAGE>

receiving Party by the disclosing Party under this Agreement, as shown by
written evidence, and is not obtained or derived directly or indirectly from the
disclosing Party;

          5.1.4 is disclosed by the receiving Party pursuant to the requirement
of law, provided that the receiving Party has complied with the provisions set
forth in Section 6.3; or

          5.1.5 is independently developed by the receiving Party without the
use of or reliance on any Information provided by the disclosing Party
hereunder, as shown by contemporaneous written evidence.

     5.2 Legal Disclosure. If the receiving Party becomes legally required to
disclose any Information provided by the disclosing Party, the receiving Party
will give the disclosing Party prompt notice of such fact so that the disclosing
Party may obtain a protective order or other appropriate remedy concerning such
disclosure and/or waive compliance with the non-disclosure provision of this
Agreement. The receiving Party will reasonably cooperate with the disclosing
Party in connection with the disclosing Party's efforts to obtain any such order
or other remedy. If any such order or other remedy does not fully preclude
disclosure or the disclosing Party waives such compliance, the receiving Party
will make such disclosure only to the extent that such disclosure is legally
required and will use its reasonable efforts to have confidential treatment
accorded to the disclosed Information.

     5.3 Public Disclosure. Except as otherwise required by law, neither Party
shall issue a press release or make any other public disclosure concerning this
Agreement or the subject matter hereof without the prior written approval of
such press release or public disclosure by the other Party. Each Party shall
submit any such press release or public disclosure to the other Party for its
prior review and approval, which approval shall not be unreasonably withheld. If
the receiving Party does not respond within fifteen (15) days from submission,
the press release or public disclosure shall be deemed approved. The contents of
any such announcement or similar publicity that has been reviewed and approved
by the reviewing Party can be re-released by either Party without a requirement
for re-approval. The principles to be observed by Schering and Molecular Insight
in public disclosures with respect to this Agreement shall be: accuracy,
compliance with applicable legal requirements, the requirements of
confidentiality under this Section 5 and normal business practice in the
pharmaceutical industry for disclosures by companies comparable to Schering and
Molecular Insight. Notwithstanding the foregoing, either Party may issue such
press releases as it determines, based on advice of counsel, are reasonably
necessary to comply with law or for appropriate market disclosure. It is
understood, however, that unless required by law, the Parties shall not disclose
the specific financial terms and conditions of this Agreement. In addition, if a
public disclosure is required by law, with the exception of any filing with the
US Securities and Exchange Commission, and provided, however, that such
exception does not apply to the disclosure of this Agreement and/or its Annexes,
nor any documents or data related to this Agreement, or the cooperation
hereunder, the disclosing Party shall provide copies of the disclosure
reasonably in advance of such filing or other disclosure for the non-disclosing
Party's prior review and comment and shall give due consideration to any
reasonable comments by the non-filing Party relating to such filing, including
without limitation the provisions of this Agreement for which confidential
treatment should be sought.

     5.4 Scientific Publications. Schering shall be permitted to publish
scientific publications in relation to the Compounds, provided that Schering
notifies Molecular Insight of any proposed publication forty-five (45) days in
advance of the proposed submission date to

                                       10

<PAGE>

enable Molecular Insight to examine the proposal and evaluate whether such
publication would endanger any patent claim Molecular Insight wishes to seek
patent protection for, in which case the Parties shall agree on a modification
of such publication which meets the interests of both Parties. In case Schering
notifies Molecular Insight that it has no interest in a patent application,
Molecular Insight shall have an additional forty-five (45) days to file any
relevant patent applications.

     5.5 Confidential Terms. Except as expressly provided herein, each Party
agrees not to disclose any terms of this Agreement to any Third Party without
the consent of the other Party; except that disclosures may be made as required
by securities or other applicable laws, or to actual or prospective investors,
corporate partners or acquirers, or to a Party's accountants, attorneys and
other professional advisors. For the avoidance of doubt, each Party may disclose
the terms of this Agreements to its Affiliates.

     5.6 Survival. This Section 5 will survive expiry or termination of this
Agreement for any reason.

6. DILIGENCE

     6.1. Development Plan. An outline of the development plan is attached to
this Agreement as Annex 6.1.

     Within ninety (90) days of the Effective Date, Molecular Insight shall
prepare a detailed development plan outlining its proposed development
activities, including anticipated timescales. The activities described in the
development plan, as amended from time to time given the exigencies of
pharmaceutical product development, shall be consistent with Molecular Insight's
diligence obligations pursuant to Section 6.2, below.

     6.2 Diligence. Molecular Insight agrees to use Commercially Reasonable
Efforts to develop and Commercialize Products in the Field in the Territory, and
obtain such approvals as may be necessary to manufacture and sell such Products.
Molecular Insight shall have full responsibility for the Development and
Commercialization of Products. All INDs and IND Equivalents and all Drug
Approval Applications will be submitted in the name of Molecular Insight, its
Affiliates or Sublicensees, and all Regulatory Approvals will belong to
Molecular Insight, its Affiliates or Sublicensees. Failure by Molecular Insight
to use Commercially Reasonable Efforts as described in this Section 6.2 will
constitute a breach of a material obligation and will permit Schering - without
prejudice to other remedies - to terminate this Agreement in accordance with
Section 10.2.

     6.3 Compliance with Standards. In respect of any Development activities to
be performed by Molecular Insight, unless expressly agreed with Schering
otherwise, Molecular Insight agrees to perform its obligations in compliance
with applicable laws, regulations and guidances, including without limitation
GCP, GLP and GMP, and the manufacturing and other commitments made in INDs, IND
Equivalents, NDAs and NDA Equivalents.

     6.4 Reports. Molecular Insight shall keep Schering informed of its
development and Commercialization activities with respect to the Compounds and
Products by semi-annually providing Schering with a written report stating the
status of development of, and Commercialization activities relating to, such
Compounds and Products.

                                       11

<PAGE>

     6.5 Development cooperation with Third Parties. In the event that Molecular
Insight considers a cooperation or partnering with Third Parties in regard to
the development of Products, it shall inform Schering accordingly. Such
information to Schering shall not be later than the first contact with a Third
Party to this regard.

7. REPRESENTATIONS AND WARRANTIES

     7.1 General Representations. Each Party hereby represents and warrants to
the other Party as follows:

          7.1.1 Such Party is a corporation duly organized, validly existing and
in good standing under the laws of the jurisdiction in which it is incorporated;

          7.1.2 Such Party has the corporate power and authority and the legal
right to enter into this Agreement and to perform its obligations hereunder and
the execution, delivery and performance by such Party of this Agreement have
been duly authorized by all necessary corporate action. This Agreement has been
duly executed and delivered on behalf of such Party, and constitutes a legal,
valid, binding obligation, enforceable against such Party in accordance with its
terms except as enforceability may be limited by (A) any applicable bankruptcy,
insolvency, reorganization, moratorium or similar law affecting creditor's
rights generally, or (B) general principles of equity, whether considered in a
proceeding in equity or at law;

          7.1.3 All necessary consents, approvals and authorizations of all
governmental authorities and other persons required to be obtained by such Party
in connection with this Agreement have been obtained; and

          7.1.4 The execution and delivery of this Agreement and the performance
of such Party's obligations hereunder (a) do not conflict with or violate any
requirement of applicable laws or regulations or any judgment, injunction,
decree, determination or award presently in effect having applicability to it,
and (b) do not conflict with, or constitute a default under, any agreement of
such Party with any Third Party.

     7.2 Additional Schering Representations and Warranties. Schering represents
and warrants to Molecular Insight as of the Effective Date as follows:

          7.2.1 The Schering Intellectual Property in the Territory is owned and
controlled solely and exclusively by Schering free and clear of any liens,
charges and encumbrances, and no Third Party has any claim of ownership with
respect to the Schering Intellectual Property in the Territory, whatsoever;

          7.2.2 Schering has not previously granted, and will not grant during
the term of this Agreement, any right, license or interest in and to the
Schering Intellectual Property in the Field in the Territory, or any portion
thereof, inconsistent or in conflict with the license granted to Molecular
Insight herein;

          7.2.3 To the best of Schering's knowledge, all patent applications
included in the Schering Patents (i) meet the best mode requirement for
obtaining a patent on the specific compound(s) BA-[list leads], pharmaceutical
compositions thereof and methods of treating or diagnosing cancer therewith,
imposed by the European Patent Office, Japanese Patent Office and the United
States Patent and Trademark Office, as applicable, and (ii) have had paid as of
the

                                       12

<PAGE>

Effective Date all maintenance and/or annuity fees necessary to keep all such
patent applications in good standing in the various jurisdictions within the
Territory in which they have been filed.

          7.2.4 There are no pending or threatened actions, suits,
investigations, claims, judgments or proceedings relating to the Schering
Intellectual Property. Schering is not aware of any issued patent that is or
would be infringed by the development or commercialization of a Product as
contemplated by this Agreement;

          7.2.5 Schering is not aware of any information relating to the
institution or threatened institution of any interference, opposition,
re-examination, reissue, revocation, nullification, or any official proceeding
challenging a Schering Patent;

          7.2.6 Annex 1.401 contains a complete and accurate list of all
Schering Patents in the Territory;

          7.2.7 Schering has disclosed to Molecular Insight or allowed Molecular
Insight access to any facts known to Schering as of the Effective Date that
Schering reasonably believes in good faith to be material regarding: (i)
preclinical and clinical study results and protocols for Compounds and/or
Products; (ii) any communications to and from any Regulatory Authority with
respect to Compounds and/or Products, including, but not limited to, any
regulatory submissions and filings, correspondence with, and minutes of meetings
and telephone conferences with Regulatory Authorities; and (iii) adverse drug
experiences and other IND safety reports with respect to Compounds and/or
Products; and

     7.3 Effect of Representations and Warranties. It is understood that if the
representations and warranties made by a Party under this Article 7 are not true
and accurate, and the other Party incurs damages, liabilities, costs or other
expenses as a result, the Party making such representations and warranties shall
indemnify and hold the other Party harmless from and against any such damages,
liabilities, costs or other expenses incurred as a result.

     7.4 Limitation of Liability. NOTWITHSTANDING ANY OTHER PROVISION CONTAINED
HEREIN TO THE CONTRARY, MOLECULAR INSIGHT SPECIFICALLY WAIVES ANY AND ALL CLAIMS
FOR DAMAGES AGAINST SCHERING OTHER THAN DIRECT DAMAGES, INCLUDING BUT NOT
LIMITED TO PUNITIVE OR EXEMPLARY DAMAGES, HOWEVER DENOMINATED, AND INDIRECT,
CONSEQUENTIAL, OR INCIDENTAL DAMAGES, WHETHER ARISING IN CONTRACT, IN TORT
(INCLUDING WITHOUT LIMITATION NEGLIGENCE), OR ANY OTHER THEORY EVEN IF INFORMED
OF THE POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL
PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN. IN NO EVENT SHALL SCHERING'S
LIABILITY FOR DIRECT DAMAGES EXCEED THE AMOUNTS RECEIVED FROM MOLECULAR INSIGHT
HEREUNDER IN THE CONTRACT YEAR DURING WHICH THE CLAIM AROSE.

     7.5 Disclaimer. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT NOTHING IN
THIS AGREEMENT IS OR SHALL BE CONSTRUED AS:

          7.5.1 A REQUIREMENT THAT SCHERING SHALL FILE ANY PATENT APPLICATION,
SECURE ANY PATENT, OR MAINTAIN ANY PATENT IN FORCE; OR

          7.5.2 AN OBLIGATION TO BRING OR PROSECUTE ACTIONS OR SUITS AGAINST

                                       13

<PAGE>

THIRD PARTIES FOR INFRINGEMENT (EXCEPT TO THE EXTENT AND IN THE CIRCUMSTANCES
STATED IN ARTICLE 10); OR

          7.5.3 GRANTING BY IMPLICATION, ESTOPPEL, OR OTHERWISE, ANY LICENSES OR
RIGHTS UNDER PATENTS OR KNOW-HOW OF SCHERING OTHER THAN THE SCHERING PATENTS AND
THE SCHERING KNOW-HOW AND SCHERING'S INTEREST IN THE JOINT PATENTS, IF ANY; OR

          7.5.4 A REPRESENTATION OR WARRANTY BY SCHERING OF THE ACCURACY,
SAFETY, OR USEFULNESS FOR ANY PURPOSE OF ANY SCHERING KNOW-HOW AT ANY TIME MADE
AVAILABLE BY SCHERING OR OF THE PATENTABILITY OF THE CLAIMS FILED.

          7.5.5 NO GUARANTEE BY SCHERING THAT ANY PRODUCT WILL EVER BE
DEVELOPED, APPROVED FOR MARKETING, SOLD OR OFFERED FOR SALE, OR IF SOLD, WILL
GENERATE REVENUES OR PROFITS FOR LICENSEE.

8. INTELLECTUAL PROPERTY

     8.1 Filing, Prosecution and Maintenance by Schering. With respect to
Schering Patents, Schering shall have the exclusive right:

          (a)  to take all reasonable steps to prosecute all pending patent
               applications included within Schering Patents;

          (b)  to respond to oppositions, nullity actions, re-examinations,
               revocation actions, interference proceedings and similar
               proceedings filed by third parties against the grant of letters
               patent for such applications;

          (c)  to maintain in force any letters patent included in Schering
               Patents by duly filing all necessary papers and paying any fees
               required by the patent laws of the particular country in which
               such letters patent were granted; and

          (d)  subject to the provisions of Section 8.1.1 herein, to cooperate
               fully with and take all necessary actions requested by Molecular
               Insight in connection with the prosecution and maintenance of any
               letters patent included in Schering Patents, including but not
               limited to (i) the filing of any continuation and/or division
               application, (ii) the filing of any patent or patent application
               in one or more extension states, and (iii) the validation of any
               regional patent in at least those regional states requested by
               Molecular Insight.

     Schering shall notify Molecular Insight in a timely manner of any decision
to not pursue an action or to abandon a pending patent application or an issued
patent included in Schering Patents. Thereafter, Molecular Insight shall have
the option, at its expense, of taking such action or continuing to prosecute any
such pending patent application or of keeping the issued patent in force, or all
of these.

                                       14

<PAGE>

          8.1.1 Copies of Documents. Schering shall in a timely manner provide
to Molecular Insight copies of all material documents received or filed in
connection with the prosecution of all Schering Patents, including office
actions, substantive responses, notices of opposition, interference and the
like, notices of allowance or grant, payments of maintenance or annuity fees,
and notices of abandonment. Prior to filing any substantive (i.e., not the mere
perfection of a formality) document in response to an office action issued
during prosecution of any Schering Patent (such as responses or amendments,
affidavits, declarations or the like), for the purpose of informing and
obtaining substantive comment from Molecular Insight patent counsel, Schering
shall in a timely manner provide drafts of such documents to Molecular Insight
so that the Parties' respective patent counsel may proceed in a cooperative
manner to formulate the content of the final version of such documents. In the
event of an initial disagreement between the Parties' respective patent counsel
as to content of such documents or related patent prosecution strategy, the
Parties hereby agree to refer such initial disagreement first to each Parties'
respective business development executives having responsibility over the
administration of this Agreement. Failing resolution of the disagreement by the
Parties' respective business development executives, the disagreement shall be
referred to and resolved by an Executive Vice President level officer of each
Party. Schering shall also provide to Molecular Insight at the end of each
calendar mid-year updates of Annex 1.41., which will include a column indicating
the next action due for each entry and the deadline for completing such next
action.

          8.1.2 Patent Extensions. Molecular Insight shall have the right to
obtain a patent term extension pursuant to 35 USC Section 156 and counterparts
in other countries with respect to one Schering Patent per country and per
Product to the extent that such extensions are available by reason of regulatory
approval of a Product under the Agreement during the period the Agreement is in
effect. Schering shall file requests for such extensions cooperatively with
Molecular Insight and, where necessary, as agent for Molecular Insight.

     8.2 Disclaimer. Neither party may disclaim a Valid Claim within Schering
Patent Rights without the consent of the other.

     8.3 Disclosure of Actual or Threatened Infringement. When information comes
to the attention of either Party to the effect that any Schering Patent has been
or is threatened to be unlawfully infringed by a Third Party, such Party shall
promptly notify the other Party and provide such other Party with the details of
all such information. Molecular Insight shall have the first right at its sole
expense to take or bring such action as it may deem necessary to prosecute or
prevent such unlawful infringement, including the right to bring or defend any
lawsuit, action and/or proceeding involving any such infringement (collectively,
hereinafter "Proceeding"). Molecular Insight shall notify Schering promptly of
the commencement of any such Proceeding. If the law of the jurisdiction of such
Proceeding provides that it is necessary for Schering to join any such
Proceeding, Schering shall, at Molecular Insight's expense, execute all papers
and perform such other acts as may be reasonably required to permit Molecular
Insight to commence and prosecute such Proceeding, in which case Molecular
Insight shall hold Schering free, clear and harmless from any and all costs and
expenses of litigation, including attorneys fees. The Parties acknowledge that
Molecular Insight shall have full control over the prosecution and any possible
settlement of such Proceeding Schering shall have the right, at its own expense,
to be independently represented in such Proceeding by counsel of its own choice.
Notwithstanding the foregoing, whether or not Schering is independently
represented by counsel, Molecular Insight shall not take a position in such
Proceeding conceding the invalidity of any claim included in a Schering Patent
without first obtaining a written consent from Schering, which consent shall not
be unreasonably withheld. Molecular Insight will also timely submit its
proposals for claim interpretation to Schering for approval prior to a Markman
hearing in US

                                       15

<PAGE>

litigation or an analogous time point in any other such Proceeding, Schering's
approval not to be unreasonably withheld. Molecular Insight shall not agree to
any settlement of such Proceeding, which would include a stipulation as to the
validity or scope of any claim included in a Schering Patent without first
obtaining a written consent from Schering, which consent shall not be
unreasonably withheld. If Molecular Insight brings such Proceeding, it shall
have the right first to reimburse itself out of any recovery from such
Proceeding or settlement thereof for all of Molecular Insight's costs and
expenses, including attorneys fees, related to such Proceedings or settlement.
The remainder, if any, of such recovery, shall be treated as Net Sales in the
calendar quarter in which any such recovery was received, entitling Schering to
receive a proportion of such remainder according to the applicable royalty rate
provided in Section 3.3.2, above. If Molecular Insight does not, within one
hundred twenty (120) days of receiving notice from or giving notice to Schering
initiate such Proceeding, Schering shall have the right, but not the obligation,
to initiate a Proceeding for such alleged infringement. Schering may join
Molecular Insight as a party plaintiff, if necessary to initiate or prosecute
such Proceeding, in which event Molecular Insight will cooperate fully to become
a party in such Proceeding and Schering shall hold Molecular Insight free, clear
and harmless from any and all costs and expenses of such litigation, including
attorneys fees. Any sums recovered in any such Proceeding or in its settlement
shall belong to Schering. The Parties acknowledge that Schering shall have full
control over the prosecution and any possible settlement of such Proceeding that
Schering initiates. Molecular Insight shall have the right to be represented by
counsel of its own selection and at its own expense in any such Proceeding
instituted by Schering.

     8.4 Defense of Infringement Claims. Molecular Insight shall have full
responsibility for any third party infringement claims against it for
Commercialization of Products, including defending against or settling such
claims, all at its own expense. Schering shall have no liability for any third
party infringement claim raised against Molecular Insight.

     8.5 New Schering patent application(s). For the avoidance of doubt, the
Parties acknowledge that Schering                  **
inter alia in relation to the Eye Technology as described in Section 2.2.

9. INDEMNIFICATION

     9.1 Schering. Schering shall indemnify, defend and hold harmless Molecular
Insight and its directors, officers, employees and agents (each a "Molecular
Insight Indemnitee") from and against any and all liabilities, damages, losses,
costs or expenses (including attorneys' and professional fees and other expenses
of litigation and/or arbitration) (a "Liability") resulting from a claim, suit
or proceeding made or brought by a Third Party against a Molecular Insight
Indemnitee arising from or occurring as a result of any breach of
representations and warranties set forth by Schering. Section 7.4 shall apply
mutatis mutandis.

     9.2 Molecular Insight. Molecular Insight shall indemnify, defend and hold
harmless Schering and its directors, officers, employees and agents (each a
"Schering Indemnitee") from and against any and all liabilities, damages,
losses, costs or expenses (including attorneys' and professional fees and. other
expenses of litigation and/or arbitration) (a "Liability") resulting from a
claim, suit or proceeding made or brought by a Third Party against a Schering
Indemnitee, arising from or occurring as a result of (i) any breach of
representations and warranties; (ii) the practice by Molecular Insight of any
right granted herein, or (iii) any development, testing,

                                       16

                       *Confidential Treatment Requested*
<PAGE>

manufacture, importation, use, offer for sale, sale or other distribution of any
Product by Molecular Insight or its Affiliates and Sublicensee (including,
without limitation, product liability claims).

     9.3 Procedure. In the event that any Indemnitee intends to claim
indemnification under this Section 10 it shall notify the other Party (the
"Indemnitor") without undue delay in writing of such alleged Liability. The
Indemnitor shall have the sole right to control the defense and settlement
thereof. The Indemnitee shall cooperate with the Indemnitor and its legal
representatives in the investigation of any action, claim or liability covered
by this Section 10 and do nothing which would adversely affect such defense or
settlement. The Indemnitee shall not, except at its own cost, voluntarily make
any payment or incur any expense with respect to any claim or suit without the
prior written consent of the Indemnitor, which the Indemnitor shall not be
required to give.

     9.4 Challenge. Schering may on thirty (30) days written notice terminate
this Agreement if Molecular Insight takes any action, serves any notice or
commences any proceedings seeking to revoke or challenge the validity of the
Schering Patent or if it procures or assists a Third Party to take such action.

     9.5 FOR THE AVOIDANCE OF DOUBT, SCHERING SHALL HAVE NO LIABILITY WHATSOEVER
TO MOLECULAR INSIGHT OR ANY OTHER PERSON FOR OR ON ACCOUNT OF ANY INJURY; LOSS;
OR DAMAGE; OF ANY KIND OR NATRUE; SUSTAINED BY; OR ANY DAMAGE ASSESSED OR
ASSERTED AGAINST; OR ANY OTHER LIABILITY INCURRED BY OR IMPOSED ON MOLECULAR
INSIGHT OR ANY OTHER PERSON; ARISING OUT OF OR IN CONNECTIONWITH OR RESULTING
FROM (A) THE PRODUCTION; USE OR SALE OF ANY PRODUCT; OR THE PRACTICE OF THE
SCHERING PATENTS; OR (B) THE USE OF ANY SCHERING KNOW HOW; AND MOLECULAR INSIGHT
SHALL HOLD SCHERING; OR ITS OFFICERS; EMPLOYEES; OR AGENTS; HARMLESS IN THE
EVENT SCHERING; OR ITS OFFICERS; EMPLOYEES; OR AGENTS IS HELD LIABLE.

     9.6 Survival. This Section 10 will survive expiry or termination of this
Agreement for any reason.

10. TERM AND TERMINATION

     10.1 Term. The term of this Agreement shall commence on the Effective Date
and unless earlier terminated as provided in this Section 11, this Agreement
shall continue in full force and effect on a country-by-country and
Product-by-Product basis until there are no remaining royalty payment
obligations in a country, at which time the Agreement shall expire in its
entirety in such country.

     10.2 Termination for Cause. Failure of Molecular Insight or Schering to
comply with any of the respective material obligations and conditions contained
in this Agreement shall entitle the other Party to give the Party in default
notice requiring it to cure such default. If such default is not cured within
ninety (90) days after receipt of such notice, the notifying Party shall be
entitled (without prejudice to any of its other rights conferred on it by the
Agreement) to terminate this Agreement by giving a notice to take effect
immediately. Notwithstanding the foregoing, in the event of a non-monetary
default, if the default is not reasonably capable of being cured within the
ninety (90) day cure period by the defaulting Party and such defaulting Party is
making a good faith effort to cure such default, the notifying Party may not
terminate this Agreement, provided

                                       17

<PAGE>

however, that the notifying Party may terminate this Agreement if such default
is not cured within one hundred and eighty (180) days of such original notice of
default. The right of either Party to terminate this Agreement as herein above
provided shall not be affected in any way by its waiver of, or failure to take
action with respect to, any previous default.

     10.3 Termination for Insolvency. If voluntary or involuntary proceedings by
or against a Party are instituted in bankruptcy under any insolvency law
(including Chapter 11), or a receiver or custodian is appointed for such Party,
or proceedings are instituted by or against such Party for corporate
reorganization or the dissolution of such Party, which proceedings, if
involuntary, shall not have been dismissed within sixty (60) days after the date
of filing, or if such Party makes an assignment for the benefit of creditors, or
substantially all of the assets of such Party are seized or attached and not
released within sixty (60) days thereafter, the other Party, may immediately
terminate this Agreement effective upon notice of such termination.

     10.4 Effect of Termination and Expiration.

          10.4.1 Accrued Rights and Obligations. Termination of this Agreement
for any reason shall not release any Party hereto from any liability which, at
the time of such termination, has already accrued to the other Party or which is
attributable to a period prior to such termination nor preclude either Party
from pursuing any rights and remedies it may have hereunder or at law or in
equity with respect to any breach of this Agreement.

          10.4.2 Return of Schering Know-How. Upon any termination of this
Agreement, Molecular Insight shall promptly return to Schering all Schering
Intellectual Property in tangible form; provided Molecular Insight may retain
one (1) copy of such tangible Schering Intellectual Property for archival
purposes and for ensuring compliance with Section 6.

          10.4.3 Stock on Hand. In the event this Agreement is terminated for
any reason, Molecular Insight shall have the right to sell or otherwise dispose
of the stock of any Product subject to this Agreement then on hand until the
first anniversary of the effective date of such termination. Sales made pursuant
to this clause shall be treated as Net Sales and royalty thereon shall be paid
to Schering.

     10.5 Survival. Sections 11.4.1 and 11.4.2 as well as Sections 5 and 9 of
this Agreement shall survive expiration or termination of this Agreement for any
reason.

11. MISCELLANEOUS

     11.1 Governing Law. This Agreement and any dispute, arising from the
performance or breach hereof shall be governed by and construed in accordance
with the laws of the state of New York. Place of proceedings shall be New York,
NY.

     11.2 Independent Contractors. The relationship of the Parties hereto is
that of independent contractors. The Parties hereto are not deemed to be agents,
partners or joint ventures of the others for any purpose as a result of this
Agreement or the transactions contemplated thereby.

     11.3 Assignment. This Agreement shall not be assignable by Molecular
Insight to any Third Party, in whole or in part, without the written consent of
Schering which consent shall not be unreasonably withheld; provided, however,
Molecular Insight may assign this Agreement without said consent if it sells all
or most of its business. Schering may assign this Agreement

                                       18

<PAGE>

with prior notice to Molecular Insight. This Agreement shall be binding upon and
inure to the benefit of the Parties and their successors and assigns.

     11.4 Notices. All notices, requests and other communications hereunder
shall be in writing and shall be personally delivered, sent by courier or by
facsimile transmission or by registered or certified mail, return receipt
requested, postage prepaid, in each case to the respective address specified
below, or such other address as may be specified in writing to the other Party
hereto:

If to Schering:                            If to Molecular Insight:

Bayer Schering Pharma Aktiengesellschaft   Molecular Insight Pharmaceuticals,
13342 Berlin                               Inc.
Germany                                    160 Second Street
Attn. Dr. Wolfgang Frohlich                Cambridge, MA 02142
Fax: +49-30-468-12853                      USA
                                           Attn. VP, Commercial & Business
With a copy to:                            Development
                                           Fax: 617-492-5664
Bayer Schering Pharma Aktiengesellschaft
13342 Berlin                               With a copy to:
Germany
Attn. Legal Department                     Joshua A. Kalkstein, Esp.
Fax: +49-30-468-14089                      Robinson & Cole, LLP
                                           One Boston Place
                                           Boston, MA 02108
                                           USA

     11.5 Force Majeure. Neither Party shall lose any rights hereunder or be
liable to the other Party for damages or losses (except for payment obligations)
on account of failure of performance by the defaulting Party if the failure is
occasioned by war, fire, act of God, earthquake, flood, embargo, or any other
reason where failure to perform is beyond the reasonable control and not caused
by the negligence, intentional conduct or misconduct if the non-performing Party
has exerted all reasonable efforts to avoid or remedy such force majeure. If the
force majeure continues for a period of more than 12 months, the Party not
relying on force majeure shall be entitled to terminate this Agreement forthwith
by written notice to the other.

     11.6 Compliance with Laws. Each Party shall furnish to the other Party any
information requested by that Party during the term of this Agreement or any
extensions hereof to enable that Party at its expense to comply with the
requirements of any government agency.

     11.7 Severability. In the event that any provisions of this Agreement are
determined to be invalid or unenforceable by a court of competent jurisdiction,
the remainder of the Agreement shall remain in full force and effect without
said provision. In such event the Parties shall, in good faith, negotiate a
substitute clause for any provision declared invalid or unenforceable, which
shall most nearly approximate the intent of the Parties entering this Agreement.

     11.8 Waiver. It is agreed that no waiver by either Party hereto of any
breach of default of any of the covenants or agreements herein set forth shall
be deemed a waiver as to any

                                       19

<PAGE>

subsequent and/or similar breach or default.

     11.9 Complete Agreement. This Agreement, with its Schedules, constitutes
the entire agreement between the Parties with respect to the subject matter
hereof, and that all prior agreements respecting the subject matter hereof,
either written or oral, expressed or implied, are merged and canceled, and are
null and void and of no effect. No amendment or change hereof or addition hereto
shall be effective or binding on either of the Parties hereto unless reduced to
writing and duly executed on behalf of both Parties.

     11.10 Use of Name. Neither Party shall use the name or trademarks of the
other Party, without the prior written consent of such other Party except in
connection with the disclosure of the existence of this Agreement, in which case
Schering shall be referred to as "Schering AG, Berlin" or as otherwise
instructed by Schering.

     11.11 Headings. The captions to the several Sections and Articles hereof
are not a part of this Agreement, but are included merely for convenience of
reference only and shall not affect its meaning or interpretation.

     11.12 Counterparts. This Agreement may be executed in two counterparts,
each of which shall be deemed an original and which together shall constitute
one instrument.

     11.13 Third Party Beneficiaries. No person, other than Schering, Molecular
Insight, their Affiliates and their assignees hereunder, shall be deemed an
intended beneficiary hereunder or have any right to enforce any obligation of
this Agreement.

     IN WITNESS WHEREOF Schering and Molecular Insight have executed this
Agreement by their respective duly authorized representatives.

BAYER SCHERING PHARMA                   MOLECULAR INSIGHT
AKTIENGESELLSCHAFT                      PHARMACEUTICALS, INC.

By:  /s/ Mattias Braentigan             By:  /s/ David S. Barlow
    ---------------------------------       ------------------------------------
Print Name:  Mattias Braentigan         Print Name:  David S. Barlow
            -------------------------               ----------------------------
Title:  Head of TRGDG                   Title: Chairman and CEO
       ------------------------------          ---------------------------------

By:  /s/ Wolfgang Froehlich
    ---------------------------------
Print Name: Wolfgang Froehlich, Ph.D.
            -------------------------
Title: Senior Manager, Out Partnering
       ------------------------------

                                       20

<PAGE>

                                   ANNEX 1.39

                                SCHERING KNOW-HOW

Schering Know-how consists of all data disclosed in the due diligence folders
provided at the meeting on June 1, 2006 with the exception of know-how in
relation to the administration of the Compounds and the use of blood-supply
modulators to reduce eye uptake in order to minimize potential side effects of
the Compounds. Included in Schering Know-how are the raw data from all
preclinical research studies, all issued and draft reports from all preclinical
studies, and all information Schering has in its possession about chemical
synthesis and formulation related to the Compounds.

                                Table of content

Folder content raw data and summary (chronologically per folder)

I

<TABLE>
<S> <C>
Compound                           Experiment                    Model
BA63                               Bio-d(i)                      C57BL6-B16/F1(ii)
IMBA (Eisenhurt et al.)            Bio-d                         C57BL6-B16/F1
BA40                               Bio-d                         Black nude SK-Mel-3(ii)
BA40                               Bio-d                         CB6F1(II)
BA40                               Bio-d                         C57BL6-B16/F1
BA60                               Bio-d                         C57BL6-B16/F1
BA61                               Bio-d                         C57BL6-B16/F1
BA44                               Bio-d                         C57BL6-B16/F1
BA45                               Bio-d                         C57BL6-B16/F1
BA45                               Bio-d                         CD-1 nu/nu(II)
BA44                               Bio-d                         CD-1 nu/nu
BA40                               Bio-d                         NMRI SK-Mel-1 & 3 & 28(ii)
-                                  Growth kinetics               CD-1 nu/nu SK-Mel 3 & 28
BA40                               RX(iii)                       C57BL6-B16/F1
-                                  Growth kinetics               C57BL6-B16/F1
-                                  Growth kinetics               NMRI SK-Mel-1 & 3 & 28
BA50                               Bio-d                         C57BL6-B16/F1
BA40                               Bio-d                         C57BL6-B16/F1

II

Compound                           Experiment                    Model
BA52                               Bio-d                         NMRI SK-Mel-3
BA40                               RX                            NMRI SK-Mel-3
BA52                               Bio-d                         C57BL6-B16/F1
BA52                               Eye uptake calculations       C57BL6-B16/F1
BA40                               Blocking of eye uptake        Mini pig
BA68                               Bio-d                         C57BL6-B16/F1
BA69                               Bio-d                         C57BL6-B16/F1
BA65                               Bio-d                         C57BL6-B16/F1
Dacarbazin                         MTD(iv) study                 NMRI SK-Mel-3
BA40                               Bio-d + imaging               C57BL6-B16/F1
BA66                               Bio-d                         C57BL6-B16/F1
BA40 + IMBA                        Bio-d + imaging               C57BL6-B16/F1
BA81                               Bio-d                         C57BL6-B16/F1
BA56                               Bio-d                         C57BL6-B16/F1

III

Compound                           Experiment                    Model
BA101                              Bio-d                         C57BL6-B16/F1
BA52                               Imaging                       C57BL6-B16/F1 + NMRI SK-Mel-3
BA100                              Bio-d                         C57BL6-B16/F1
BA95                               Bio-d                         C57BL6-B16/F1
BA93                               Bio-d                         C57BL6-B16/F1
BA91                               Bio-d                         C57BL6-B16/F1
BA52                               Eye tox                       C57BL6-B16/F1
BA52                               Bio-d                         NMRI SK-Mel-3
BA52                               RX                            NMRI SK-Mel-3
BA67                               Bio-d                         C57BL6-B16/F1
BA59                               Bio-d                         C57BL6-B16/F1
BA40                               Bio-d                         NMRI SK-Mel-3
BA40                               Bio-d; imaging; eye blocking  C57BL6-B16/F1
BA40                               Microautoradiography          C57BL6-B16/F1
BA80                               Bio-d                         C57BL6-B16/F1

IV

Compound                           Experiment                    Model
BA52                               Imaging                       Mini pig
BA52                               Imaging                       NMRI SK-Mel-3
BA52                               Bio-d                         CB6F1

V

Compound                           Experiment                    Model
BA52                               Microautoradiography          C57BL6-B16/F1
BA52                               Eye uptake                    Human vs. mini pig

VI

Compound                           Experiment                    Model
BA52                               Confidential summary          -
BA52                               Case reports                  Patients - VI
</TABLE>

                                       21
<PAGE>

                                   ANNEX 1.40

                                SCHERING PATENTS

<TABLE>
<CAPTION>
Country   Type      Filing        Filing Number     Publication   Process      Date           Nature       Expiration
-------   ----      ------        -------------     -----------   -------      ----           ------       ----------
<S>       <C>    <C>           <C>                  <C>           <C>       <C>          <C>               <C>
   AR     NP1    10/Mar/2005   P 050100925                          FLG     10/03/2005   P 050100925       10/03/2025
   BO     NP1    10/Mar/2005   SP-250047                            FLG     10/03/2005   SP-250047         10/03/2025
   CL     NP1    10/Mar/2005   0507-2005                            FLG     10/03/2005   0507-2005
   DE     NP1    10/Mar/2004   102004011720.9       29/Sep/2005     PUB     29/09/2005   DE                10/03/2024
                                                                                         102004011720A1
   GT     NP1    10/Mar/2005   PI-2005-0046                         FLG     10/09/2005   PI-2005-0046      10/03/2025
   MT     NP1    03/Mar/2005   2654                                 FLG     03/03/2005   2654              03/03/2025
   MY     NP1    08/Mar/2005   PI20050946                           FLG     08/03/2005   PI20050946
   PA     NP1    10/Mar/2005   86260-01                             FLG     10/03/2005   86260-01          10/03/2025
   PE     NP1    10/Mar/2005   000276-2005                          FLG     10/03/2005   000276-2005       10/03/2025
   SV     NP1    10/Mar/2005   E-3385-2005                          FLG     10/03/2005   E-3385-2005       10/03/2025
   TH     NP1    08/Mar/2005   098358                               FLG     08/03/2005   098358            08/03/2025
   TW     NP1    10/Mar/2005   094107360                            FLG     10/03/2005   094107360         10/03/2025
   US     NP1    10/Mar/2005   11/076023            22/Sep/2005     PUB     22/09/2005   US 2005-          10/03/2025
                                                                                         0207972A1
   US     PSP1   10/Mar/2004   60/551356                            FLG     10/03/2004   60/551356         10/03/2005
   UY     NP1    10/Mar/2005   28801                19/Aug/2005     FLG     10/03/2005   28801             10/03/2025
   VE     NP1    10/Mar/2005   2005-000421                          FLG     10/03/2005   2005-000421
   WO     PCT1   10/Mar/2005   PCT/EP2005/002 553   29/Sep/2005     PUB     29/09/2005   WO2005/089815A2
</TABLE>

                                       22

<PAGE>

                                    ANNEX 1.7

                            DESCRIPTION OF COMPOUNDS

Compounds are benzamides structurally identical to BA 43-BA 102 or derivatives
thereof as disclosed in the due diligence folders provided to Molecular Insight
on June 1, 2006.

                                       23

<PAGE>
                                   ANNEX 2.6

                GENERAL NUMBERING SCHEME FOR BENZAMIDE COMPOUNDS

<TABLE>
COMPOUND     PRECURSOR     AMOUNT     I-127 REF.    AMOUNT
 CODE       (ZK-NUMBER)     (MG)     (ZK-NUMBER)     (MG)
--------    -----------    ------    -----------    ------
<S>         <C>            <C>       <C>            <C>
BA40         Bromopride     25        304261         --
BA41             304257     --        307504         --
BA42             304258     --        307504         --
BA43             304259     --            --         --
BA44             253063     20        308747         10
BA45             253062      3        308748         --
BA50             253060     50        251428         50
BA52             316027     --        319402         20
BA53             319401     --        319400         --
BA56             253061     60        201854         --
BA59             264376      5        268968         10
BA60             253065     15        262591         15
BA61             253066     30        262594         18
BA62             253067     10        262583         10
BA63             802105     10        262597         --
BA65             253069     20        268969         15
BA66             266104     30        268970         20
BA67             267714     15        269270         5
BA68             268815      5        342087         10
BA69             268814     20        342088         15
BA70             268813     20        342089         17
BA71             268818     10        KQ 265         --
BA72             259754     30        KQ 266         --
BA73             268819     25        342101         10
BA80             253064     30                       --
BA81             253068     40        264450         --
BA90             279328      5        342100         --
BA91             325910     25        358344         20
BA92             325914     45        358345         34
BA93             325915     10        358346         28
BA94             325917     30       K.Q.276         10
BA95             325916     10        358358         14
BA96             325918     40        358350         20
BA97             325919     50       K.Q.278         20
BA98             343960     50        358367         30
BA99             343968     --       K.Q.291         --
BA100            343969     10        358368         20
BA101            343971     --        358369         20
BA102            343973     10        358370         25
</TABLE>

All precursors and non-radioactively iodinated compounds were characterized by
HPLC, (1)H-NMR-, MS, IR- and UV-spectroscopy. The radioiodinated benzamides
were characterized by HPLC comparison to the non-radioactive I-127 benzamide
standard.

                                      24

<PAGE>

                                    ANNEX 6.1

                            OUTLINE DEVELOPMENT PLAN

                       ANNEX 6.1 --ZK-BA DEVELOPMENT PLAN

                              [PERFORMANCE GRAPH]

                                       25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]